BRUKER CORP (Form: 10-Q, Received: 08/09/2010 14:58:04)

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

For the quarterly period ended June 30, 2010

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

For the transition period from to

Commission File Number 000-30833

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		04-3110160
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

40 Manning Road, Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (978) 663-3660

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “accelerated filer, large accelerated filer, smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer x
Non-accelerated filer o		Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at August 3, 2010
Common Stock, $0.01 par value per share		164,769,064 shares

Table of Contents

B RUKER CORPORATION

Quarterly Report on Form 10-Q

For the Quarter Ended June 30, 2010

Index

		Page
Part I	FINANCIAL INFORMATION	1
Item 1:	Unaudited Condensed Consolidated Financial Statements	1
	Unaudited Condensed Consolidated Balance Sheets as of June 30, 2010 and December 31, 2009	1
	Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2010 and 2009	2
	Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009	3
	Notes to Unaudited Condensed Consolidated Financial Statements	4
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	34
Item 4:	Controls and Procedures	35
Part II	OTHER INFORMATION	35
Item 1:	Legal Proceedings	35
Item 1A:	Risk Factors	35
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 3:	Defaults Upon Senior Securities	36
Item 4:	[Removed and Reserved]	36
Item 5:	Other Information	36
Item 6:	Exhibits	36
	Signatures	37

Table of Contents

PART I FINANCIAL INFORMATION

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share data)

	June 30,			December 31,
	2010			2009
ASSETS
Current assets:
Cash and cash equivalents	$	187.6		$	207.1
Restricted cash	2.5			2.0
Accounts receivable, net	161.5			184.1
Inventory	424.5			422.8
Other current assets	58.5			57.5
Total current assets	834.6			873.5

Property, plant and equipment, net	199.3			223.4
Intangibles and other long-term assets	106.6			75.1
Total assets	$	1,140.5		$	1,172.0

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—		$	0.1
Current portion of long-term debt	25.1			21.9
Accounts payable	53.6			49.8
Customer advances	212.0			219.2
Other current liabilities	252.5			249.2
Total current liabilities	543.2			540.2

Long-term debt	101.6			115.7
Other long-term liabilities	83.1			97.3
Commitments and contingencies (Note 18)	—			—

Shareholders’ Equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding at June 30, 2010 and December 31, 2009	—			—
Common stock, $0.01 par value 260,000,000 shares authorized, 164,786,346 and 164,384,679 shares issued and 164,769,127 and 164,371,384 outstanding at June 30, 2010 and December 31, 2009, respectively	1.6			1.6
Treasury stock at cost, 17,219 at June 30, 2010 and 13,295 at December 31, 2009	(0.2		)	(0.1		)
Other shareholders’ equity	409.5			415.7
Total shareholders’ equity attributable to Bruker Corporation	410.9			417.2
Noncontrolling interest in consolidated subsidiaries	1.7			1.6
Total shareholders’ equity	412.6			418.8

Total liabilities and shareholders’ equity	$	1,140.5		$	1,172.0

The accompanying notes are an integral part of these statements.

Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2010			2009			2010			2009
Product revenue	$	267.0		$	222.9		$	511.0		$	425.1
Service revenue	32.5			28.3			64.0			55.2
Other revenue	1.4			1.3			3.6			2.7
Total revenue	300.9			252.5			578.6			483.0

Cost of product revenue	149.1			125.2			283.3			236.9
Cost of service revenue	16.1			16.1			33.3			32.2
Total cost of revenue	165.2			141.3			316.6			269.1
Gross profit	135.7			111.2			262.0			213.9

Operating expenses:
Selling, general and administrative	64.0			60.4			129.7			118.9
Research and development	31.2			31.1			64.0			60.2
Amortization of acquisition-related intangible assets	0.7			0.5			1.1			0.9
Other charges (credits), net	1.9			(1.0		)	2.4			(0.6		)
Total operating expenses	97.8			91.0			197.2			179.4

Operating income	37.9			20.2			64.8			34.5

Interest and other income (expense), net	(4.2		)	(2.9		)	(4.5		)	(2.8		)

Income before income taxes and noncontrolling interest in consolidated subsidiaries	33.7			17.3			60.3			31.7
Income tax provision	10.8			4.6			21.4			10.4

Consolidated net income	22.9			12.7			38.9			21.3
Net income (loss) attributable to noncontrolling interest in consolidated subsidiaries	0.3			(0.2		)	0.2			—
Net income attributable to Bruker Corporation	$	22.6		$	12.9		$	38.7		$	21.3

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.14		$	0.08		$	0.24		$	0.13
Diluted	$	0.14		$	0.08		$	0.23		$	0.13

Weighted average common shares outstanding:
Basic	164.3			163.3			164.2			163.3
Diluted	165.8			164.7			165.7			164.5

The accompanying notes are an integral part of these statements.

Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

	Six Months Ended
	June 30,
	2010			2009
Cash flows from operating activities:
Consolidated net income	$	38.9		$	21.3
Adjustments to reconcile consolidated net income to cash flows from operating activities:
Depreciation and amortization	14.7			13.5
Amortization of deferred financing costs	0.3			0.3
Stock-based compensation	3.3			3.3
Deferred income taxes	(8.2		)	(1.8		)
Gain on bargain purchase	—			(2.1		)
Other non-cash expense	2.9			0.3
Changes in operating assets and liabilities:
Accounts receivable	9.4			40.3
Inventories	(37.6		)	(4.5		)
Accounts payable	9.3			(2.3		)
Customer advances	13.8			(4.7		)
Other changes in operating assets and liabilities, net	6.3			(12.3		)
Net cash provided by operating activities	53.1			51.3

Cash flows from investing activities:
Purchases of property, plant and equipment	(10.7		)	(7.1		)
Acquisitions, net of cash acquired	(37.8		)	(1.1		)
Net cash used in investing activities	(48.5		)	(8.2		)

Cash flows from financing activities:
Repayments of revolving lines of credit, net	(0.4		)	(35.8		)
Repayment of term debt	(9.9		)	(15.9		)
Changes in restricted cash	(0.7		)	(0.5		)
Issuance of common stock under stock plans	2.2			0.1
Cash payments to noncontrolling interests	(0.1		)	—
Net cash used in financing activities	(8.9		)	(52.1		)
Effect of exchange rate changes on cash and cash equivalents	(15.2		)	(4.6		)
Net change in cash and cash equivalents	(19.5		)	(13.6		)
Cash and cash equivalents at beginning of period	207.1			166.2
Cash and cash equivalents at end of period	$	187.6		$	152.6

The accompanying notes are an integral part of these statements.

Table of Contents

BRUKER CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Business

Bruker Corporation and its wholly-owned subsidiaries (the “Company”) is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications. The Company’s core technology platforms include X-ray technologies, magnetic resonance technologies, mass spectrometry technologies, optical emission spectroscopy and infrared and Raman molecular spectroscopy technologies. The Company also manufactures and distributes a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. The Company also develops and manufactures low temperature and high temperature superconducting wire and superconducting devices for use in advanced magnet technology, physics research and energy applications. The Company maintains major technical and manufacturing centers in Europe, North America and Japan, and has sales offices located throughout the world. The Company’s diverse customer base includes life science, pharmaceutical, biotechnology and molecular diagnostic research companies, academic institutions, advanced materials and semiconductor industries and government agencies.

Management reports results on the basis of the following two segments:

· Scientific Instruments. The operations of this segment include the design, manufacture and distribution of advanced instrumentation and automated solutions based on X-ray technology, spark-optical emission spectroscopy technology, atomic force microscopy technology, magnetic resonance technology, mass spectrometry technology and infrared and Raman molecular spectroscopy technology. Typical customers of the Scientific Instruments segment include pharmaceutical, biotechnology, and molecular diagnostic companies; academic institutions; medical schools; other non-profit organizations; clinical microbiology laboratories; government departments and agencies; nanotechnology, semiconductor, chemical, cement, metals and petroleum companies; and food, beverage and agricultural analysis companies and laboratories.

· Energy & Supercon Technologies. The operations of this segment include the development and marketing of superconducting and non-superconducting materials and devices for growing markets in renewable energy, energy infrastructure, healthcare and “big science” research. This segment supplies low temperature superconductors for use in magnetic resonance imaging and nuclear magnetic resonance systems, fusion energy research and other applications, as well as high temperature superconductors which are primarily used in fusion energy research. This segment also provides superconductivity-enabled devices, such as magnets, accelerator cavities and modules, radio frequency power couplers and linear accelerators, primarily for use in fusion research and other scientific applications. In addition, this segment has a number of devices and materials under development, including superconducting crystal growth magnets for photovoltaic and semiconductor applications, inductive superconducting fault current limiters for energy infrastructure applications and high temperature superconductors for compact high-power wind turbine generators and other applications. Typical customers of the Energy & Supercon Technologies segment include manufacturers of medical technology and life science analytics tools and universities and dedicated research facilities in the fields of material sciences, energy, biotechnology and proteomics, among others.

The financial statements represent the consolidated accounts of the Company. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2010 and 2009 have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation have been included. The results for interim periods are not necessarily indicative of the results expected for the full year. Certain prior year amounts have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net income or shareholders’ equity.

Table of Contents

2. Acquisitions

On May 19, 2010, the Company completed the acquisition of three former Varian, Inc. (“Varian”), product lines which Agilent Technologies, Inc. (“Agilent”) divested in connection with obtaining regulatory approval for its May 14, 2010 acquisition of Varian. The Company acquired certain assets and assumed certain liabilities in Varian’s inductively coupled plasma mass spectrometry instruments business, laboratory gas chromatography instruments business, and gas chromatography triple-quadrupole mass spectrometry instruments business (collectively, the “chemical analysis business”) for cash consideration of $37.5 million. The acquired business complements the Company’s existing mass spectrometry products and expands the Company’s offerings to industrial and applied markets. The acquisition of the chemical analysis business is being accounted for under the acquisition method. The Company has not yet completed the final allocation of the purchase price but has preliminarily allocated the consideration transferred as follows:

Inventory	$	13.0
Property, plant and equipment	2.8
Intangible assets	9.7
Goodwill	22.0
Liabilities assumed	(10.0		)
	$	37.5

The allocation of the purchase price will be completed within the measurement period.

The results of the chemical analysis business have been included in the Scientific Instruments segment from the date of acquisition. Pro forma financial information reflecting the acquisition of the chemical analysis business has not been presented because the impact on revenues, net income and net income per common share attributable to Bruker Corporation shareholders is not material.

In April 2009, the Company acquired substantially all of the assets of the research instruments portion of ACCEL Instruments GmbH (the “RI business”) from Varian Medical Systems, Inc. The acquisition of the RI business was accounted for under the acquisition method. The RI business, located in Bergisch Gladbach, Germany, consists of the development and manufacture of electron and ion linear accelerators, superconducting and normal conducting accelerator cavities, insertion devices, superconducting fault current limiters, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. The consideration transferred in acquiring the RI business was approximately $0.4 million and consisted entirely of cash. The Company acquired approximately $2.8 million of receivables, $4.4 million of inventory, $2.2 million of other current assets and $4.9 million of property, plant and equipment in this acquisition and assumed approximately $12.1 million of current liabilities. The Company also recorded $0.5 million representing the fair value of a noncontrolling interest. In 2009, in connection with the acquisition of the RI business, the Company recorded a gain of approximately $1.3 million that was recorded as a component of acquisition-related charges in the consolidated statements of operations. A gain of $2.1 million was initially recorded in the second quarter of 2009 based on a preliminary purchase price allocation, but was subsequently reduced by $0.8 million in the fourth quarter of 2009 based on the final allocation. The results of the RI business have been included in the Energy & Supercon Technologies segment from the date of acquisition. Pro forma financial information reflecting the acquisition of the RI business has not been presented because the impact on revenues, net income and net income per common share attributable to Bruker Corporation shareholders is not material.

3. Stock-Based Compensation

The Company’s primary types of share-based compensation are in the form of stock options and restricted stock. The Company recorded stock-based compensation expense for the three and six months ended June 30, 2010 and 2009 as follows (in millions):

Table of Contents

	Three Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009
Stock options	$	1.5	$	1.2	$	2.8	$	2.5
Restricted stock	0.2		0.3		0.5		0.8
Total stock-based compensation, pre-tax	1.7		1.5		3.3		3.3
Tax benefit	0.2		0.2		0.5		0.6
Total stock-based compensation, net of tax	$	1.5	$	1.3	$	2.8	$	2.7

Compensation expense is amortized on a straight-line basis over the underlying vesting terms. Stock options to purchase the Company’s common stock are periodically awarded to executive officers and other employees of the Company subject to a vesting period of three to five years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions regarding volatility, expected life, dividend yield and risk-free interest rate are required for the Black-Scholes model and are presented in the table below:

	2010		2009
Risk-free interest rate	2.42%-3.46%		1.71%-3.60%
Expected life	6.5 years		6.5 years
Volatility	62.0	%	64.0	%
Expected dividend yield	0.0	%	0.0	%

The risk-free interest rate is the yield on zero-coupon U.S. Treasury securities for a period that is commensurate with the expected life assumption. Expected life is determined through the simplified method as defined in the Securities and Exchange Commission Staff Accounting Bulletin No. 110. The Company believes that this is the best estimate of the expected life of a new option. Expected volatility can be based on a number of factors but the Company currently believes that the exclusive use of historical volatility results in the best estimate of the grant-date fair value of employee stock options because it reflects the market’s current expectations of future volatility. Expected dividend yield was not considered in the option pricing formula since the Company does not pay dividends and has no current plans to do so in the future. The terms of some of the Company’s indebtedness also currently restrict its ability to pay dividends to its shareholders.

Bruker Corporation Stock Plan

In February 2010, the Bruker BioSciences Corporation Amended and Restated 2000 Stock Option Plan (the “2000 Plan”) expired at the end of its scheduled ten-year term. On March 9, 2010, the Company’s Board of Directors unanimously approved and adopted the Bruker Corporation 2010 Incentive Compensation Plan (the “2010 Plan”) and on May 14, 2010, the 2010 Plan was approved by the Company’s stockholders. The 2010 Plan provides for the issuance of up to 8,000,000 shares of the Company’s common stock. The Plan allows a committee of the Board of Directors (the “Committee”) to grant incentive stock options, non-qualified stock options and restricted stock awards. The Committee has the authority to determine which employees will receive the awards, the amount of the awards and other terms and conditions of the award. Awards granted by the Committee typically vest over a period of three to five years.

At June 30, 2010, the Company expects to recognize pre-tax stock-based compensation expense of $12.6 million associated with outstanding stock option awards granted under the Company’s stock plans over the weighted average remaining service period of 1.8 years. In addition, the Company expects to recognize additional pre-tax stock-based compensation expense of $1.9 million associated with outstanding restricted stock awards granted under the Plan over the weighted average remaining service period of one year.

Bruker Energy & Supercon Technologies Stock Plan

In October 2009, the Board of Directors of Bruker Energy & Supercon Technologies, Inc. (“BEST”), a wholly-owned direct subsidiary of the Company, adopted the Bruker Energy & Supercon Technologies, Inc. 2009 Stock Option Plan (the “BEST Plan”). The BEST Plan provides for the issuance of up to 1,600,000 shares of BEST common stock in connection with awards under the Plan. The Plan allows a committee of the BEST Board of Directors to grant incentive stock options and non-qualified stock options.

At June 30, 2010, the Company expects to recognize pre-tax stock-based compensation expense of $1.5 million associated

Table of Contents

with outstanding stock option awards granted under the BEST Plan over the weighted average remaining service period of 4.3 years.

4. Earnings Per Share

Net income per share is calculated by dividing net income by the weighted-average shares outstanding during the period. The diluted net income per share computation includes the effect of shares which would be issuable upon the exercise of outstanding stock options and the vesting of restricted stock, reduced by the number of shares, which are assumed to be purchased by the Company from the resulting proceeds at the average market price during the period.

The following table sets forth the computation of basic and diluted average shares outstanding for the three and six months ended June 30, 2010 and 2009 (in millions, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009
Net income attributable to Bruker Corporation	$	22.6	$	12.9	$	38.7	$	21.3

Weighted average shares outstanding:
Weighted average shares outstanding-basic	164.3		163.3		164.2		163.3
Effect of dilutive securities:
Stock options and restricted stock	1.5		1.4		1.5		1.2
	165.8		164.7		165.7		164.5

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.14	$	0.08	$	0.24	$	0.13
Diluted	$	0.14	$	0.08	$	0.23	$	0.13

Stock options to purchase approximately 0.4 million shares and 3.3 million shares were excluded from the computation of diluted earnings per share in the three months ended June 30, 2010 and 2009, respectively, and approximately 0.4 million shares and 3.5 million shares were excluded from the computation of diluted earnings per share in the six months ended June 30, 2010 and 2009, respectively, because the exercise price of the stock options exceeded the average market price of the Company’s common stock and, as a result, would have had an anti-dilutive effect.

5. Fair Value of Financial Instruments

The Company applies the following hierarchy, which prioritizes the input used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The three levels are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The Company measures the following financial assets and liabilities at fair value on a recurring basis. The fair value of these financial assets and liabilities was determined using the following inputs at June 30, 2010 (in millions):

Table of Contents

			Quoted Prices in Active Markets Available		Significant Other Observable Inputs		Significant Unobservable Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
Assets:
Cash equivalents	$	93.1	$	93.1	$	—	$	—
Embedded Derivatives in Purchases and Delivery Contracts	0.3		—		0.3		—
Total assets recorded at fair value	$	93.4	$	93.1	$	0.3	$	—

Liabilities:
Interest rate swap	$	3.7	$	—	$	3.7	$	—
Embedded derivatives in purchase and delivery contracts	4.1		—		4.1		—
Foreign exchange contracts	1.3		—		1.3		—
Total liabilities recorded at fair value	$	9.1	$	—	$	9.1	$	—

The Company’s financial instruments consist primarily of cash equivalents, derivative instruments consisting of forward contracts, options and an interest rate swap, accounts receivable, short-term borrowings, accounts payable and long-term debt. The carrying amounts of the Company’s cash equivalents, accounts receivable, short-term borrowings and accounts payable approximate fair value due to their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The fair value of derivative instruments is based on quotes received from third party banks. These values represent the estimated amount the Company would receive or pay to terminate the agreements taking into consideration current foreign exchange or interest rates, as well as the creditworthiness of the counterparty. The Company’s long-term debt consists primarily of variable rate arrangements with interest rates that reset every three months and, as a result, reflect current interest rates. Consequently, the carrying value of the Company’s long-term debt approximates fair value.

6. Inventories

Inventories consisted of the following as of June 30, 2010 and December 31, 2009 (in millions):

	June 30, 2010		December 31, 2009
Raw materials	$	115.2	$	108.8
Work-in-process	149.6		134.6
Demonstration units	40.7		41.3
Finished goods	119.0		138.1
Inventories	$	424.5	$	422.8

The Company reduces the carrying value of its demonstration inventories for differences between its cost and estimated net realizable value through a charge to cost of revenue that is based on a number of factors including the age of the unit, the physical condition of the unit and an assessment of technological obsolescence. Amounts recorded in cost of product revenue related to the write-down of demonstration units to net realizable value were $5.6 million and $6.1 million for the three months ended June 30, 2010 and 2009, respectively and $11.2 million and $11.9 million for the six months ended June 30, 2010 and 2009, respectively.

Finished goods include in-transit systems that have been shipped to the Company’s customers but have not yet been installed and accepted by the customer. As of June 30, 2010 and December 31, 2009, inventory-in-transit was $57.7 million and $80.8 million, respectively.

7. Goodwill and Other Intangible Assets

The following table sets forth the changes in the carrying amount of goodwill for the six months ended June 30, 2010 (in millions):

Table of Contents

Balance at December 31, 2009	$	47.5
Goodwill acquired during the period	22.3
Foreign currency impact	(3.6		)
Balance at June 30, 2010	$	66.2

Goodwill is not amortized, instead, goodwill is tested for impairment on a reporting unit basis annually, or on an interim basis when events or changes in circumstances warrant. The Company performed its annual test for impairment as of December 31, 2009 and determined that goodwill and other intangible assets were not impaired at that time. The Company did not identify any indicators of impairment during the six month period ended June 30, 2010.

The following is a summary of other intangible assets subject to amortization at June 30, 2010 and December 31, 2009 (in millions):

	June 30, 2010							December 31, 2009
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Existing technology and related patents	$	19.4	$	(11.4	)	$	8.0	$	14.4	$	(10.7	)	$	3.7
Customer relationships	5.9		(1.4		)	4.5		2.0		(0.9		)	1.1
Trade names	0.7		(0.3		)	0.4		0.4		(0.3		)	0.1
Intangible assets subject to amortization, net	$	26.0	$	(13.1	)	$	12.9	$	16.8	$	(11.9	)	$	4.9

For the three months ended June 30, 2010 and 2009, the Company recorded amortization expense of $0.7 million and $0.5 million, respectively, related to intangible assets subject to amortization. For the six months ended June 30, 2010 and 2009, the Company recorded amortization expense of $1.2 million and $0.9 million, respectively, related to intangible assets subject to amortization.

8. Debt

At June 30, 2010 and December 31, 2009, the Company’s debt obligations consisted of the following (in millions):

	June 30,			December 31,
	2010			2009
US Dollar term loan under the Credit Agreement	$	121.9		$	131.3

Euro bank loans at fixed rate of 2.95%, collateralized by land and buildings of Bruker Daltonik GmbH, quarterly principal payments and monthly interest payments due and payable through 2010	—			0.3

Capital lease obligations	4.8			6.0
Total long-term debt	126.7			137.6
Current portion of long-term debt	(25.1		)	(21.9		)
Total long-term debt, less current portion	$	101.6		$	115.7

In 2008, the Company entered into a credit agreement with a syndication of lenders (the “Credit Agreement”) which provides for a revolving credit line with a maximum commitment of $230.0 million and a term facility of $150.0 million. The outstanding principal and interest under the term loan is payable in quarterly installments through December 2012. Borrowings under the Credit Agreement bear interest, at the Company’s option, at either (i) the higher of the prime rate or the federal funds rate plus 0.50%, or (ii) adjusted LIBOR, plus margins ranging from 0.40% to 1.25% and a facility fee ranging from 0.10% to 0.20%. As of June 30, 2010, the weighted average interest rate of borrowings under the term facility of the Credit Agreement was approximately 2.7%.

Borrowings under the Credit Agreement are secured by the pledge to the banks of 100% of the capital stock of each of the Company’s wholly-owned domestic subsidiaries and 65% of the capital stock of certain of the Company’s direct or indirect wholly-owned foreign subsidiaries. The Credit Agreement also requires the Company to maintain certain financial ratios related to leverage ratios and interest coverage ratios as defined in the Credit Agreement. In addition to the financial ratios, the

Table of Contents

Credit Agreement restricts, among other things, the Company’s ability to do the following: make certain payments; incur additional debt; incur certain liens; make certain investments, including derivative agreements; merge, consolidate, sell or transfer all or substantially all of the Company’s assets; and enter into certain transactions with affiliates. As of June 30, 2010, the latest measurement date, the Company was in compliance with the covenants under the Credit Agreement.

In addition to its long-term arrangements, the Company had the following amounts outstanding under revolving loan arrangements:

	June 30,		December 31,
	2010		2009
Revolving loans under the Credit Agreement	$	—	$	—
Other revolving loans	—		0.1
Total short-term borrowings	$	—	$	0.1

The following is a summary of the maximum commitments and net amounts available to the Company under revolving loans as of June 30, 2010 (in millions):

	Weighted Average Interest Rate		Total Amount Committed by Lenders		Outstanding Borrowings		Outstanding Letters of Credit		Total Amount Available
Credit Agreement	—	%	$	230.0	$	—	$	1.4	$	228.6
Other revolving loans	—	%	90.7		—		76.5		14.2
Total revolving loans			$	320.7	$	—	$	77.9	$	242.8

Other revolving loans are with various financial institutions located primarily in Germany, Switzerland and France. The Company’s other revolving lines of credit are typically due upon demand with interest payable monthly. Certain of these lines of credit are unsecured while others are secured by the accounts receivable and inventory of the related subsidiary.

9. Derivative Instruments and Hedging Activities

Interest Rate Risks

The Company’s exposure to interest rate risk relates primarily to outstanding variable rate debt and adverse movements in the related short-term market rates. The most significant component of the Company’s interest rate risk relates to amounts outstanding under the Credit Agreement. In April 2008, the Company entered into an interest rate swap arrangement to manage its exposure to interest rate movements and the related effect on its variable rate debt. Under this interest rate swap arrangement, the Company will pay a fixed rate of approximately 3.8% and receive a variable rate based on three month LIBOR. The initial notional amount of this interest rate swap was $90.0 million and it amortizes in proportion to the term debt component of the Credit Agreement through December 2012. At June 30, 2010, the notional amount of this interest rate swap was $73.1 million. The Company concluded that this swap met the criteria to qualify as an effective hedge of the variability of cash flows of the interest payments and accounts for the interest rate swap as a cash flow hedge. Accordingly, the Company reflects changes in the fair value of the effective portion of this interest rate swap in accumulated other comprehensive income, a component of shareholders’ equity. As of June 30, 2010 and December 31, 2009, the Company recorded a liability of $3.7 million and $3.5 million, respectively, related to the fair value of the interest rate swap that is recorded in other current liabilities in the consolidated balance sheets. Amounts recorded in accumulated other comprehensive income (loss) are reclassified to interest and other income (expense), net in the consolidated statement of operations when either the forecasted transaction occurs or it becomes probable that the forecasted transaction will not occur. The Company expects $2.2 million of the accumulated loss to be reclassified into earnings over the next twelve months.

Foreign Exchange Rate Risk Management

The Company generates a substantial portion of its revenues and expenses in international markets, principally Europe and Japan, which subjects its operations to the exposure of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company, from time to time, has entered into foreign currency contracts in order to minimize the volatility that fluctuations in currency exchange rates have on the Company’s cash flows

Table of Contents

related to purchases and sales denominated in foreign currencies.

The Company periodically enters into foreign currency contracts, primarily forward and option contracts, to minimize the volatility that fluctuations in currency exchange rates have on the Company’s cash flows related to purchases and sales denominated in foreign currencies. Under these arrangements, the Company typically agrees to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. Dollars or other currencies on specified dates with maturities of less than two years. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in interest and other income (expense), net in the consolidated statements of operations. At June 30, 2010, and December 31, 2009, the following foreign currency contracts were outstanding:

		Notional Amount
Buy	Sell	June 30, 2010		December 31, 2009
Euro	U.S. Dollars	$	20.8	$	5.5
Swiss Francs	U.S. Dollars	12.6		13.1
Japanese Yen	Euro	0.1		—
U.S. Dollars	Euro	—		6.7
		$	33.5	$	25.3

In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $35.8 million for the delivery of products and $0.2 million for the purchase of products at June 30, 2010 and $30.4 million for the delivery of products and $0.2 million for the purchase of products at December 31, 2009. The changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the consolidated statements of operations.

The fair value of the foreign exchange derivative instruments described above is recorded in our consolidated balance sheets for the periods ended June 30, 2010 and December 31, 2009 as follows (in millions):

		Fair Value
	Balance Sheet Location	June 30, 2010		December 31, 2009
Derivative assets:
Embedded derivatives in purchase and delivery contracts	Other current assets	$	0.3	$	—
Foreign exchange contracts	Other current assets	—		—

Derivative liabilities:
Interest rate swap contract	Other current liabilities	$	3.7	$	3.5
Embedded derivatives in purchase and delivery contracts	Other current liabilities	4.1		1.5
Foreign exchange contracts	Other current liabilities	1.3		—

The losses recognized in other comprehensive income related to the effective portion of the interest rate swap designated as a hedging instrument for the three and six months ended June 30, 2010 and 2009 are as follows (in millions):

	Three Months Ended June 30,					Six Months Ended June 30,
	2010			2009		2010			2009
Interest rate swap contract	$	(0.6	)	$	0.5	$	(1.5	)	$	0.1

The losses related to the effective portion of the interest rate swap designated as a hedging instrument that were reclassified from other comprehensive income and recognized in net income for the three and six months ended June 30, 2010 and 2009 are as follows (in millions):

Table of Contents

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
Interest rate swap contract	$	(0.7	)	$	(0.6	)	$	(1.4	)	$	(1.1	)

The Company did not recognize any amounts related to ineffectiveness in the results of operations for the three and six months ended June 30, 2010 and 2009.

The impact on net income of changes in the fair value of derivative instruments not designated as hedging instruments for the three and six months ended June 30, 2010 and 2009 are as follows (in millions):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
Foreign exchange contracts	$	(1.1	)	$	(0.3	)	$	(1.3	)	$	—
Embedded derivatives in purchase and delivery contracts	(1.6		)	(1.0		)	(2.3		)	0.6
Income (expense), net	$	(2.7	)	$	(1.3	)	$	(3.6	)	$	0.6

The amounts recorded in the results of operations related to derivative instruments not designated as hedging instruments are recorded in interest and other income (expense), net.

10. Other Charges (Credits), Net

The components of other charges (credits), net, were as follows for the three and six months ended June 30, 2010 and 2009 (in millions):

	Three Months Ended June 30,					Six Months Ended June 30,
	2010		2009			2010		2009

Acquisition-related charges	$	0.4	$	0.4		$	0.7	$	0.8
Transition-related charges incurred in connection with acquired businesses	0.5		—			0.5		—
Loss on divestiture of businesses	1.0		—			1.0		—
Restructuring charges (Note 11)	—		—			0.2		—
Impairment charges (Note 12)	—		0.7			—		0.7
Gain on bargain purchase (Note 2)	—		(2.1		)	—		(2.1		)
Other charges (credits), net	$	1.9	$	(1.0	)	$	2.4	$	(0.6	)

11. Restructuring Charges

In the first quarter of 2010, the Company recorded restructuring charges of $0.2 million, which related primarily to severance incurred in connection with the closing of a production facility in Herzogenrath, Germany and relocating the associated operations. These charges were recorded in the Scientific Instruments segment. The Company does not expect to incur any additional costs related to this move and expects to have made all of the severance payments by the end of the 2010. The liability for restructuring charges is recorded in other current liabilities in the unaudited condensed consolidated balance sheets. The charges related to this restructuring reserve are as follows (in millions):

Table of Contents

	Total		Severance
Balance at December 31, 2009	$	—	$	—
Restructuring charges	0.2		0.2
Cash payments	—		—
Foreign currency impact	—		—
Balance at June 30, 2010	$	0.2	$	0.2

12. Impairment Charges

In the second quarter of 2009, the Company recorded an impairment charge of $0.7 million, which consisted of certain fixed assets used in the production of certain superconducting wire. The impairment loss was recorded because the Company determined that the carrying value of the assets exceeded their fair value based on the estimated undiscounted operating cash flows generated by those assets. The impairment charge was allocated to the Energy & Supercon Technologies segment and has been recorded as a component of other charges (credits), net in the unaudited condensed consolidated statements of operations.

13. Employee Benefit Plans

Substantially all of the Company’s employees in Switzerland, France and Japan, as well as certain employees in Germany, are covered by Company-sponsored defined benefit pension plans. Retirement benefits are generally earned based on years of service and compensation during active employment. Eligibility is generally determined in accordance with local statutory requirements; however, the level of benefits and terms of vesting varies among plans.

The net periodic pension cost consists of the following components for the three and six months ended June 30, 2010 and 2009 (in millions):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
Components of net periodic benefit costs:
Service cost	$	1.1		$	1.1		$	2.0		$	2.0
Interest cost	1.3			1.0			2.5			2.0
Expected return on plan assets	(0.9		)	(1.0		)	(1.8		)	(1.9		)
Amortization of prior service costs	0.2			—			0.5			—
Net periodic benefit costs	$	1.7		$	1.1		$	3.2		$	2.1

The Company made contributions of $1.3 million to its defined benefit plans during the six months ended June 30, 2010 and estimates contributions of $1.3 million will be made during the remainder of 2010.

14. Interest and Other Income (Expense), Net

The components of interest and other income (expense), net, were as follows for the three and six months ended June 30, 2010 and 2009 (in millions):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
Interest income	$	0.2		$	0.4		$	0.3		$	0.8
Interest expense	(1.3		)	(2.1		)	(2.8		)	(4.4		)
Exchange gains (losses) on foreign currency transactions	(2.4		)	(0.7		)	(1.9		)	0.6
Other	(0.7		)	(0.5		)	(0.1		)	0.2
Interest and other income (expense), net	$	(4.2	)	$	(2.9	)	$	(4.5	)	$	(2.8	)

15. Provision for Income Taxes

The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and

Table of Contents

liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company also accounts for uncertain tax positions that have reached a minimum recognition threshold.

The income tax provision for the three months ended June 30, 2010 and 2009 was $10.8 million and $4.6 million, respectively, representing effective tax rates of 32.0% and 26.6%, respectively. The income tax provision for the six months ended June 30, 2010 and 2009 was $21.4 million and $10.4 million, respectively, representing effective tax rates of 35.5% and 32.8%, respectively. The Company’s effective tax rate generally reflects the tax provision (benefit) for non-U.S. entities only, since no benefit was recognized for cumulative losses incurred in the U.S. A full valuation allowance will be maintained against all U.S. deferred tax assets, including U.S. net operating losses and tax credits, until evidence exists that it is more likely than not that the loss carryforward and credit amounts will be utilized to offset U.S. taxable income. The Company’s tax rate may change over time as the amount or mix of income and taxes outside the U.S. changes. The effective tax rate is calculated using projected annual pre-tax income or loss and is affected by research and development tax credits, the expected level of other tax benefits, the impact of changes to the valuation allowance, and changes in the mix of the Company’s pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

The Company has unrecognized tax benefits of approximately $24.3 million as of June 30, 2010, of which $15.9 million, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of June 30, 2010 and December 31, 2009, approximately $4.3 million and $3.8 million, respectively, of accrued interest and penalties related to uncertain tax positions was included in other current liabilities on the unaudited condensed consolidated balance sheets. Penalties and interest related to unrecognized tax benefits in the provision for income taxes of $0.3 million and $0.2 million were recorded during the three months ended June 30, 2010 and 2009, respectively, and $0.5 million and $0.4 million were recorded during the six months ended June 30, 2010 and 2009, respectively.

The Company files returns in many foreign and state jurisdictions with varying statutes of limitations, but considers its significant tax jurisdictions to include the United States, Germany and Switzerland. The tax years 2003 to 2009 are open tax years in these major taxing jurisdictions. One of the Company’s Swiss entities is currently being audited for the tax years 2003 through 2006 and the audit is expected to be completed during 2010. In addition, a majority of the Company’s German subsidiaries are under tax audit for the years 2003 through 2008. The Company cannot reasonably predict the timing or outcome of these audits.

16. Accumulated Other Comprehensive Income (Loss)

Comprehensive income (loss) refers to revenues, expenses, gains and losses that under GAAP are included in other comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity, net of tax. The following is a summary of comprehensive income (loss) for the three and six months ended June 30, 2010 and 2009 (in millions):

Table of Contents

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
Consolidated net income	$	22.9		$	12.7		$	38.9		$	21.3
Foreign currency translation adjustments	(30.7		)	22.7			(50.7		)	(3.7		)
Unrealized gains (losses) on interest rate swap:
Unrealized holding gains (losses) arising during the period	(0.6		)	0.5			(1.5		)	0.1
Less reclassification adjustments for settlements included in the determination of net income (loss)	0.7			0.6			1.4			1.1
Pension liability adjustments	0.3			—			0.4			1.0
Total comprehensive income (loss)	(7.4		)	36.5			(11.5		)	19.8
Less: Comprehensive income (loss) attributable to noncontrolling interests	0.3			(0.2		)	0.2			—
Comprehensive income (loss) attributable to Bruker Corporation	$	(7.7	)	$	36.7		$	(11.7	)	$	19.8

17. Noncontrolling Interests

Net income (loss) attributable to noncontrolling interests for the three months ended June 30, 2010 and 2009 was $0.3 million and $(0.2) million, respectively. Net income (loss) attributable to noncontrolling interests for the six months ended June 30, 2010 and 2009 was $0.2 million and $0.0 million, respectively. The net income (loss) attributable to noncontrolling interests represents the minority shareholders’ proportionate share of the net loss recorded by five majority-owned indirect subsidiaries, Bruker Baltic Ltd., Bruker Labmate Pvt. Ltd., InCoaTec GmbH and Perch Solutions OY, which are included in the Scientific Instruments segment, and RI Research Instruments GmbH, which is included in the Energy & Supercon Technologies segment.

In the second quarter of 2010, the Company sold its ownership interest in Bruker Baltic Ltd. to one of its minority shareholders as part of its efforts to consolidate production. In addition, the Company made a payment of $0.1 million to the minority shareholders of RI Research Instruments GmbH during the second quarter of 2010.

18. Commitments and Contingencies

Legal

Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. The Company believes the outcome of these proceedings, if any, will not have a material impact on the Company’s financial position or results of operations. As of June 30, 2010 and December 31, 2009, no accruals have been recorded for such potential contingencies.

Letters of Credit and Guarantees

At June 30, 2010 and December 31, 2009, the Company had bank guarantees of $77.9 million and $87.0 million, respectively, for its customer advances. These arrangements guarantee the refund of advance payments received from customers in the event that the merchandise is not delivered in compliance with the terms of the contract. Certain of these guarantees affect the availability of the Company’s lines of credit.

19. Business Segment Information

The Company’s reportable segments are organized by the types of products and services provided. The Company has combined the Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics operating segments into the Scientific Instruments reporting segment because each has similar economic characteristics, product processes and services, types and classes of customers, methods of distribution and regulatory environments.

Table of Contents

Management evaluates segment operating performance and allocates resources based on operating income (loss). The Company uses this measure because it helps provide an understanding of our core operating results. Selected business segment information is presented below for the three and six months ended June 30, 2010 and 2009 (in millions):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
Revenue:
Scientific Instruments	$	284.9		$	241.3		$	545.2		$	464.9
Energy & Supercon Technologies	18.1			13.7			38.8			21.8
Eliminations (a)	(2.1		)	(2.5		)	(5.4		)	(3.7		)
Total revenue	$	300.9		$	252.5		$	578.6		$	483.0

Operating Income (Loss):
Scientific Instruments	$	40.4		$	20.4		$	68.1		$	36.5
Energy & Supercon Technologies	(1.7		)	(0.7		)	(2.2		)	(3.1		)
Corporate, eliminations and other (b)	(0.8		)	0.5			(1.1		)	1.1
Total operating income	$	37.9		$	20.2		$	64.8		$	34.5

(a) Represents product and service revenue between reportable segments.

(b) Represents corporate costs and eliminations not allocated to the reportable segments.

Total assets by segment as of June 30, 2010 and December 31, 2009 are as follows (in millions):

	June 30,			December 31,
	2010			2009
Assets:
Scientific Instruments	$	1,120.4		$	1,139.7
Energy & Supercon Technologies	59.6			70.3
Eliminations and other (a)	(39.5		)	(38.0		)
Total assets	$	1,140.5		$	1,172.0

(a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.

20. Recent Accounting Pronouncements

In September 2009, the Emerging Issues Task Force reached consensus on FASB Accounting Standards Update 2009-14, Software (Topic 985)—Certain Revenue Arrangements That Include Software Elements . FASB Accounting Standards Updates 2009-14 changes the accounting model for revenue arrangements that include both tangible products and software elements. Under this guidance, tangible products containing software components and non-software components that function together to deliver the tangible product’s essential functionality are excluded from the software revenue guidance in Subtopic 985-605, Software-Revenue Recognition . In addition, hardware components of a tangible product containing software components are always excluded from the software revenue guidance. FASB Accounting Standards Updates 2009-14 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, however, early adoption is permitted. The Company is currently assessing the impact that this update will have on its results of operations and financial position and when the Company will adopt these requirements.

In September 2009, the Emerging Issues Task Force reached consensus on FASB Accounting Standards Update 2009-13, Revenue Recognition (Topic 605)—Multiple-Deliverable Revenue Arrangements. FASB Accounting Standards Update 2009-13 addresses the accounting for multiple-deliverable arrangements to enable vendors to account for products or services separately rather than as a combined unit. Specifically, this guidance amends the criteria in Subtopic 605-25, Revenue Recognition-Multiple-Element Arrangements, for separating consideration in multiple-deliverable arrangements. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence; (b) third-party evidence; or (c) estimates. This guidance also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. In addition, this guidance significantly expands required disclosures related to a vendor’s multiple-deliverable revenue arrangements. FASB Accounting Standards Update 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, however, early

Table of Contents

adoption is permitted. The Company is currently assessing the impact that this update will have on its results of operations and financial position and when the Company will adopt these requirements.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2009.

Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations, which express that we “believe,” “anticipate,” “plan,” “expect,” “seek,” “estimate,” or “should,” as well as other statements, which are not historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. Actual events or results may differ materially from those set forth in forward-looking statements. Certain factors that might cause such a difference are discussed in “Factors Affecting Our Business, Operating Results and Financial Condition” set forth in our Annual Report on Form 10-K for the year ended December 31, 2009.

OVERVIEW

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, describes the principal factors affecting the results of our operations, financial condition and changes in financial condition, as well as our critical accounting policies and estimates. Our MD&A is organized as follows:

· Executive overview . This section provides a general description and history of our business, a brief discussion of our reportable segments, significant recent developments in our business and other opportunities, challenges we face and risks that may impact our business in the future.

· Critical accounting policies . This section discusses the accounting estimates that are considered important to our financial position and results of operations and that require us to exercise subjective or complex judgments in their application.

· Results of operations . This section provides our analysis of the significant line items on our unaudited condensed consolidated statement of operations for the three and six months ended June 30, 2010 compared to the three and six months ended June 30, 2009.

· Liquidity and capital resources . This section provides an analysis of our liquidity and cash flow and discussions of our outstanding debt and commitments and matters relating to our common stock.

· Recent accounting pronouncements . This section provides information about new accounting standards that have been issued but for which adoption is not yet required.

EXECUTIVE OVERVIEW

Business Overview

Bruker Corporation and its wholly-owned subsidiaries design, manufacture, service and market proprietary life science and materials research systems based on its core technology platforms, including X-ray technologies, magnetic resonance technologies, mass spectrometry technologies, optical emission spectroscopy and infrared and Raman molecular spectroscopy technologies. We sell a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosive, or CBRNE, detection. We also develop and manufacture low temperature and high temperature superconducting wire products and superconducting wire and superconducting devices for use in advanced magnet technology, physics research and energy applications. Our diverse customer base includes life science, pharmaceutical, biotechnology and molecular diagnostic research companies, academic institutions, advanced materials and semiconductor industries and government agencies. We maintain major technical and manufacturing centers in Europe, North America and Japan and we have sales offices located throughout

Table of Contents

the world. Our corporate headquarters are located in Billerica, Massachusetts.

Our business strategy is to capitalize on our ability to innovate and generate rapid revenue performance, both organically and through acquisitions. Our revenue growth strategy, combined with anticipated improvements to our gross profit margins and increased leverage on our research and development, sales and marketing and distribution investments and general and administrative expenses, is expected to enhance our operating margins and improve our earnings in the future.

On May 19, 2010, we completed our acquisition of three former Varian product lines which Agilent divested in connection with obtaining regulatory approval for its May 14, 2010 acquisition of Varian. The Company acquired certain assets and assumed certain liabilities in Varian’s inductively coupled plasma mass spectrometry instruments business, laboratory gas chromatography instruments business, and gas chromatography triple-quadrupole mass spectrometry instruments business (collectively, the “chemical analysis business”). The chemical analysis business complements our existing mass spectrometry products and expands our offerings to industrial and applied markets and provides opportunities to supply customers with equipment packages that have a broader range of applications and value.

We are organized into five operating segments, representing each of our five divisions: Bruker AXS, Bruker BioSpin, Bruker Daltonics, Bruker Optics and Bruker Energy & Supercon Technologies. Bruker AXS is in the business of manufacturing and distributing advanced X-ray, spark-optical emission spectroscopy and atomic force microscopy instrumentation used in non-destructive molecular and elemental analysis. Bruker BioSpin is in the business of manufacturing and distributing enabling life science tools based on magnetic resonance technology. Bruker Daltonics is in the business of manufacturing and distributing mass spectrometry instruments that can be integrated and used along with other analytical instruments, as well as our CBRNE detection products. Bruker Optics is in the business of manufacturing and distributing research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. Bruker Energy & Supercon Technologies is in the business of developing and producing superconductivity-based materials and superconductivity-enabled devices.

We have combined the Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics operating segments into the Scientific Instruments reporting segment because each has similar economic characteristics, product processes and services, types and classes of customers, methods of distribution and regulatory environments. As such, management reports its results based on the following segments:

· Scientific Instruments. The operations of this segment include the design, manufacture and distribution of advanced instrumentation and automated solutions based on X-ray technology, spark-optical emission spectroscopy technology, atomic force microscopy, magnetic resonance technology, mass spectrometry technology and infrared and Raman molecular spectroscopy technology. Typical customers of the Scientific Instruments segment include pharmaceutical, biotechnology and diagnostic companies; academic institutions; medical schools; other non-profit organizations; clinical microbiology laboratories; government departments and agencies; nanotechnology, semiconductor, chemical, cement, metals and petroleum companies; and food, beverage and agricultural analysis companies and laboratories.

Financial Overview

For the three months ended June 30, 2010, our revenue increased by $48.4 million, or 19.2%, to $300.9 million, compared

Table of Contents

to $252.5 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $5.9 million from the impact of foreign exchange due to the strengthening of the U.S. Dollar versus the Euro and other foreign currencies and an increase of approximately $3.7 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $50.6 million, or 20.0%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $44.5 million, or 18.4%, and the Energy & Supercon Technologies segment, which increased by $5.6 million, or 40.9%. Revenue in the Scientific Instruments segment reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. Revenues in the Energy & Supercon Technologies segment increased due to higher demand for low temperature superconducting wire.

For the six months ended June 30, 2010, our revenue increased by $95.6 million, or 19.8%, to $578.6 million, compared to $483.0 million for the comparable period in 2009. Included in this change in revenue is an increase of approximately $12.8 million from the impact of foreign exchange due to the weakening of the U.S. Dollar versus the Euro and other foreign currencies and $10.5 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $72.3 million, or 15.0%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $63.7 million, or 13.7%, and the Energy & Supercon Technologies segment, which increased by $10.3 million, or 47.2%. Revenue in the Scientific Instruments segment reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. Revenues in the Energy & Supercon Technologies segment increased due to higher demand for low temperature superconducting wire.

The mix of products sold in the Scientific Instruments segment in the three and six months ended June 30, 2010 reflects increased demand from academic, government and industrial customers. We attribute the increase in sales of magnetic resonance and mass spectrometry products and spending by academic and government customers to our new product introductions over the last twelve to eighteen months and to stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. The improvement in revenues from our industrial customers continues to reflect an ongoing improvement in these markets. We remain optimistic that the industrial markets we serve will continue to improve but we will continue to monitor the recovery in these markets. We are also monitoring the developments in academic and government research budgets, primarily in Europe. While many European governments have announced their intentions to reduce overall spending, we believe that funding for the majority of our products and markets will remain stable, or grow in some cases, in most of our key European markets.

Income from operations for the three months ended June 30, 2010 was $37.9 million, resulting in an operating margin of 12.6%, compared to income from operations of $20.2 million, resulting in an operating margin of 8.0%, for the comparable period in 2009. The increase in operating margin is primarily the result of the higher revenue described above and the corresponding improvement in our gross profit margins. Our gross profit margin for the second quarter of 2010 was 45.1%, compared with 44.0% for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products and the weakening of the Euro, which favorably impacts our gross profit margins as a majority of our production is performed in Europe. The increase in revenue allowed us to better utilize our production facilities and leverage our fixed production costs. The increase in revenue also allowed us to leverage our selling, general and administrative costs and our research and development costs, which decreased to 31.6% of revenue for the three months ended June 30, 2010 compared with 36.2% of revenue for the comparable period of 2009.

Income from operations for the six months ended June 30, 2010 was $64.8 million, resulting in an operating margin of 11.2%, compared to income from operations of $34.5 million, resulting in an operating margin of 7.1%, for the comparable period in 2009. The increase in operating margin is primarily the result of higher revenue described above and the corresponding improvement in our gross profit margins. Our gross profit margin as a percentage of revenue was 45.3% for the first half of 2010 and 44.3% for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products. The increase in revenue allowed us to better utilize our production facilities and leverage our fixed production costs. The increase in revenue also allowed us to leverage our selling, general and administrative costs and our research and development costs, which decreased to 33.5% of revenue for the six months ended June 30, 2010 compared with 37.1% of revenue for the comparable period of 2009.

We incurred approximately $2.8 million of interest expense during the six months ended June 30, 2010 compared to $4.4

Table of Contents

million for the comparable period in 2009. Of the total interest expense incurred in the first half of 2010, approximately $2.4 million related to a credit facility that we entered into during the first quarter of 2008. We initially borrowed $351.0 million under this credit facility in order to finance the acquisition of Bruker BioSpin. In the first half of 2010, we repaid approximately $9.4 million of the amounts outstanding under this credit agreement and, from the inception of this agreement, we have reduced the net amount outstanding by approximately $229.1 million.

Our effective tax rate for the three months ended June 30, 2010 was 32.0%, compared to 26.6% for the comparable period in 2009. Our effective tax rate for the six months ended June 30, 2010 was 35.5%, compared to 32.8% for the comparable period in 2009. The change in our effective tax rate relates primarily to the amount and mix of income and taxes outside the U.S. because we are not able to record a tax benefit on losses incurred in the U.S.

Our net income attributable to the shareholders of Bruker Corporation for the three months ended June 30, 2010 was $22.6 million, or $0.14 per diluted share, compared to $12.9 million, or $0.08 per diluted share, for the comparable period in 2009. Our net income attributable to the shareholders of Bruker Corporation for the six months ended June 30, 2010 was $38.7 million, or $0.23 per diluted share, compared to $21.3 million, or $0.13 per diluted share, for the comparable period in 2009.

CRITICAL ACCOUNTING POLICIES

This discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to revenue recognition, income taxes, allowance for doubtful accounts, inventories, goodwill, other intangible assets and long-lived assets, warranty costs and derivative financial instruments. We base our estimates and judgments on historical experience, current market and economic conditions, industry trends and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

We believe the following critical accounting policies to be both those most important to the portrayal of our financial position and results of operations and those that require the most subjective judgment.

Revenue recognition. We recognize revenue from system sales when persuasive evidence of an arrangement exists, the price is fixed or determinable, title and risk of loss has been transferred to the customer and collectability of the resulting receivable is reasonably assured. Title and risk of loss generally are transferred to the customer upon receipt of a signed customer acceptance form for a system that has been shipped, installed, and for which the customer has been trained. As a result, the timing of customer acceptance or readiness could cause our reported revenues to differ materially from expectations. When products are sold through an independent distributor or a strategic distribution partner who assumes responsibility for installation, we recognize the system sale when the product has been shipped and title and risk of loss have been transferred to the distributor. Our distributors do not have price protection rights or rights of return; however, our products are typically warranted to be free from defect for a period of one year. Revenue is deferred until cash is received when collectability is not reasonably assured, such as when a significant portion of the fee is due over one year after delivery, installation and acceptance of a system. For arrangements with multiple elements, we recognize revenue for each element based on the relative fair value of the elements, provided all other criteria for revenue recognition have been met. The fair value for each element provided in multiple element arrangements is typically determined by referencing the prices charged when the element is sold separately. If there is objective and reliable evidence of the fair value of the undelivered items in an arrangement, but no such evidence for the delivered items, we use the residual method to allocate the arrangement consideration. Changes in our ability to establish the fair value for each element in multiple element arrangements could affect the timing of revenue recognition. Revenue from accessories and parts is recognized upon shipment and service revenue is recognized as the services are performed. We also have contracts for which we apply the percentage-of-completion method for revenue recognition. Application of the percentage-of-completion method requires us to make reasonable estimates of the extent of progress toward completion of the contract and the total costs we will incur under the contract. Changes in our estimates could affect the timing of revenue recognition. Grant revenue is recognized when we complete the services required under the grant.

Income taxes. The determination of income tax expense requires us to make certain estimates and judgments concerning

Table of Contents

the calculation of deferred tax assets and liabilities, as well as the deductions, carryforwards and credits that are available to reduce taxable income. Deferred tax assets and liabilities arise from differences in the timing of the recognition of revenue and expenses for financial statement and tax purposes. Deferred tax assets and liabilities are measured using the tax rates in effect for the year in which these temporary differences are expected to be settled. We estimate the degree to which tax assets and loss carryforwards will result in a benefit based on expected profitability by tax jurisdiction, and we provide a valuation allowance for tax assets and loss carryforwards that we believe will more likely than not go unused. If it becomes more likely than not that a tax asset or loss carryforward will be used for which a reserve has been provided, we reverse the related valuation allowance. If our actual future taxable income by tax jurisdiction differs from estimates, additional allowances or reversals of reserves may be necessary. In addition, we only recognize benefits for tax positions that we believe are more likely than not of being sustained upon review by a taxing authority with knowledge of all relevant information. We reevaluate our uncertain tax positions on a quarterly basis and any changes to these positions as a result of tax audits, tax laws or other facts and circumstances could result in additional charges to operations.

Allowance for doubtful accounts. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to pay amounts due. If the financial condition of our customers were to deteriorate, reducing their ability to make payments, additional allowances would be required, resulting in a charge to operations.

Inventories. Inventories are stated at the lower of cost or market, with costs determined by the first-in, first-out method for a majority of subsidiaries and by average cost for certain international subsidiaries. We record provisions to account for excess and obsolete inventory to reflect the expected non-saleable or non-refundable inventory based on an evaluation of slow moving products. Inventories also include demonstration units located in our demonstration laboratories or installed at the sites of potential customers. We consider our demonstration units to be available for sale. We reduce the carrying value of demonstration inventories for differences between cost and estimated net realizable value, taking into consideration usage in the preceding twelve months, expected demand, technological obsolescence and other information including the physical condition of the unit. If ultimate usage or demand varies significantly from expected usage or demand, additional write-downs may be required, resulting in additional charges to operations.

Goodwill, other intangible assets and other long-lived assets. We evaluate whether goodwill is impaired annually and when events occur or circumstances change. We test goodwill for impairment at the reporting unit level (the operating segment or one level below an operating segment). The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. We generally determine the fair value of our reporting units using an income approach methodology of valuation that includes the discounted cash flow method. Estimating the fair value of the reporting units requires significant judgments by management about the future cash flows. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, we perform the second step of the goodwill impairment test to measure the amount of the impairment. In the second step of the goodwill impairment test we compare the implied fair value of the reporting unit’s goodwill with the carrying value of that goodwill. We also review finite-lived intangible assets and other long-lived assets when indication of potential impairment exists, such as a significant reduction in undiscounted cash flows associated with the assets. Should the fair value of our long-lived assets decline because of reduced operating performance, market declines, or other indicators of impairment, a charge to operations for impairment may be necessary.

Warranty costs. We normally provide a one year parts and labor warranty with the purchase of equipment. The anticipated cost for this warranty is accrued upon recognition of the sale based on historical warranty rates and our assumptions of future warranty claims. The warranty accrual is included as a current liability on the consolidated balance sheets. Although our products undergo quality assurance and testing procedures throughout the production process, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Although our actual warranty costs have historically been consistent with expectations, to the extent warranty claim activity or costs associated with servicing those claims differ from our estimates, revisions to the warranty accrual may be required.

Derivative financial instruments. All derivative instruments are recorded as assets or liabilities at fair value, which is calculated as an estimate of the future cash flows, and subsequent changes in a derivative’s fair value are recognized in income, unless specific hedge accounting criteria are met. Changes in the fair value of a derivative that is highly effective and designated as a cash flow hedge are recognized in accumulated other comprehensive income until the forecasted transaction occurs or it becomes probable that the forecasted transaction will not occur. We perform an assessment at the inception of the hedge and on a quarterly basis thereafter, to determine whether our derivatives are highly effective in offsetting changes in the

Table of Contents

value of the hedged items. Any changes in the fair value resulting from hedge ineffectiveness are immediately recognized as income or expense.

RESULTS OF OPERATIONS

Three Months Ended June 30, 2010 compared to the Three Months Ended June 30, 2009

Consolidated Results

The following table presents our results for the three months ended June 30, 2010 and 2009 (dollars in millions, except per share data):

	Three Months Ended
	June 30,
	2010			2009
Product revenue	$	267.0		$	222.9
Service revenue	32.5			28.3
Other revenue	1.4			1.3
Total revenue	300.9			252.5

Cost of product revenue	149.1			125.2
Cost of service revenue	16.1			16.1
Total cost of revenue	165.2			141.3
Gross profit	135.7			111.2

Operating expenses:
Selling, general and administrative	64.0			60.4
Research and development	31.2			31.1
Amortization of acquisition-related intangible assets	0.7			0.5
Other charges (credits), net	1.9			(1.0		)
Total operating expenses	97.8			91.0
Operating income	37.9			20.2

Interest and other income (expense), net	(4.2		)	(2.9		)
Income before income taxes and noncontrolling interest in consolidated subsidiaries	33.7			17.3
Income tax provision	10.8			4.6
Consolidated net income	22.9			12.7
Net income (loss) attributable to noncontrolling interest in consolidated subsidiaries	0.3			(0.2		)
Net income attributable to Bruker Corporation	$	22.6		$	12.9

Net income per common share attributable to Bruker Corporation shareholders:
Basic and diluted	$	0.14		$	0.08

Weighted average common shares outstanding:
Basic	164.3			163.3
Diluted	165.8			164.7

Revenue

For the three months ended June 30, 2010, our revenue increased by $48.4 million, or 19.2%, to $300.9 million, compared to $252.5 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $5.9 million from the impact of foreign exchange due to the strengthening of the U.S. Dollar versus the Euro and other foreign currencies and an increase of approximately $3.7 million attributable to acquisition. Excluding the effect of foreign exchange

Table of Contents

and acquisition, revenue increased by $50.6 million, or 20.0%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $44.5 million, or 18.4%, and the Energy & Supercon Technologies segment, which increased by $5.6 million, or 40.9%. Revenue in the Scientific Instruments segment reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. Revenues in the Energy & Supercon Technologies segment increased due to higher demand for low temperature superconducting wire.

The mix of products sold in the Scientific Instruments segment reflects increased demand from academic, government and industrial customers. We attribute the increase in sales of magnetic resonance and mass spectrometry products and spending by academic and government customers to our new product introductions over the last twelve to eighteen months and to stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. The improvement in revenues from our industrial customers continues to reflect an ongoing improvement in these markets. We remain optimistic that the industrial markets we serve will continue to improve but we will continue to monitor the recovery in these markets. We are also monitoring academic and government research budgets, primarily in Europe. While many European governments have announced their intentions to reduce overall spending, we believe that funding for the majority of our products and markets will remain stable, or grow in some cases, in most of our key European markets.

Cost of Revenue

Our cost of product and service revenue for the three months ended June 30, 2010, was $165.2 million, resulting in a gross profit margin of 45.1%, compared to cost of product and service revenue of $141.3 million, resulting in a gross profit margin of 44.0%, for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products and the weakening of the Euro, which favorably impacts our gross profit margins as a majority of our production is performed in Europe. The increase in revenue also allowed us to better utilize our production facilities and leverage our fixed production costs. We also reduced production costs through various cost saving initiatives.

Selling, General and Administrative

Our selling, general and administrative expense for the three months ended June 30, 2010 increased to $64.0 million, or 21.3% of revenue, from $60.4 million, or 23.9% of revenue, for the comparable period in 2009. The increase in selling, general and administrative expense is attributable to increases in headcount in support of our revenue growth and acquisitions. Increases in selling, general and administrative expenses were offset, in part, by changes in foreign currency exchange rates, primarily the Euro.

Research and Development

Our research and development expense for the three months ended June 30, 2010 increased to $31.2 million, or 10.4% of revenue, and was essentially flat compared with research and development expense of $31.1 million, or 12.3% of revenue, for the comparable period in 2009. Research and development expenses increased in the second quarter of 2010 compared with the second quarter of 2009 as a result of increases in headcount in support of new product development and acquisitions; however, these increases were offset by changes in foreign currency exchange rates, primarily the Euro, as the majority of our research and development is preformed in Europe.

Amortization of Acquisition-Related Intangible Assets

Our amortization expense from acquisition-related intangible assets was $0.7 million for the three months ended June 30, 2010 compared with $0.5 million for the comparable period in 2009. The increase in amortization expense relates to intangible assets acquired in connection with the chemical analysis business from Agilent.

Other Charges (Credits), Net

Other charges (credits), net of $1.9 million in the second quarter of 2010 related entirely to the Scientific Instruments segment and include a loss of $1.0 million associated with the sale of our investment in Bruker Baltic Ltd., a manufacturing site located in Riga, Latvia that was engaged in the production of certain components used in our X-ray product lines. We

Table of Contents

divested this business as part of our broader corporate strategy of reducing costs and consolidating critical production and know-how in certain key production sites. In addition, other charges (credits), net in the second quarter of 2010 includes $0.5 million of transition-related costs and $0.4 million of acquisition-related costs incurred in connection with our acquisition of the chemical analysis business from Agilent.

Acquisition-related credits of $(1.0) million in the second quarter of 2009 relate entirely to the Energy and Supercon Technologies segment and include a bargain purchase gain of $2.1 million recorded in connection with the acquisition of the research instruments business from Varian Medical Systems, Inc. offset, in part, by $0.4 million of transaction costs incurred in connection with the acquisition of the research instruments business and $0.7 million of impairment charges associated with certain fixed assets used in the production of certain superconducting wire.

Interest and Other Income (Expense), Net

Interest and other income (expense), net during the three months ended June 30, 2010 was $(4.2) million, compared to $(2.9) million for the comparable period of 2009.

During the three months ended June 30, 2010, the major components within interest and other income (expense), net were realized and unrealized losses on foreign currency transactions of $2.4 million and net interest expense of $1.1 million. During the three months ended June 30, 2009, the major component within interest and other income (expense), net, were net interest expense of $1.7 million and realized and unrealized losses on foreign currency transactions of $0.7 million.

The decrease in interest expense is a function of lower outstanding debt, as we reduced our total debt by $11.0 million in the first half of 2010. Losses on foreign currency exchange rates in the second quarter of 2010 were primarily a function of changes in exchange rates between the Euro and the Swiss Franc.

Income Tax Provision

Our effective tax rate generally reflects our tax provision for non-U.S. entities only since no benefit was recognized for losses incurred in the U.S. We will maintain a full valuation allowance against all U.S. deferred tax assets, including our U.S. net operating losses and tax credits, until evidence exists that it is more likely than not that the loss carryforward and credit amounts will be utilized to offset U.S. taxable income. Our tax rate may change over time as the amount and mix of income and taxes outside the U.S. changes. The effective tax rate is calculated using our projected annual pre-tax income or loss and is affected by tax credits, the expected level of other tax benefits, and the impact of changes to the valuation allowance, as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

The income tax provision for the three months ended June 30, 2010, was $10.8 million compared to $4.6 million for the three months ended June 30, 2009, representing effective tax rates of 32.0% and 26.6%, respectively. This change in our effective tax rate relates primarily to the amount and mix of income and taxes outside of the U.S.

Net Income (Loss) Attributable to Noncontrolling Interests

Net income (loss) attributable to noncontrolling interests for the three months ended June 30, 2010 was $0.3 million compared to $(0.2) million for the comparable period of 2009. Net income (loss) attributable to noncontrolling interests represents the minority shareholders’ proportionate share of the net income (loss) recorded by five majority-owned indirect subsidiaries, Bruker Baltic Ltd., Bruker Labmate Pvt. Ltd., InCoaTec GmbH and Perch Solutions OY, which are included in the Scientific Instruments segment, and RI Research Instruments GmbH, which is included in the Energy & Supercon Technologies segment.

Net Income Attributable to Bruker Corporation

Our net income for the three months ended June 30, 2010, was $22.6 million, or $0.14 per diluted share, compared to $12.9 million, or $0.08 per diluted share for the comparable period in 2009.

Table of Contents

Segment Results

Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment for the three months ended June 30, 2010 and 2009 (dollars in millions):

	Three Months Ended June 30,						Dollar		Percentage
	2010			2009			Change		Change
Scientific Instruments	$	284.9		$	241.3		$	43.6	18.1	%
Energy & Supercon Technologies	18.1			13.7			4.4		32.1	%
Eliminations (a)	(2.1		)	(2.5		)	0.4
	$	300.9		$	252.5		$	48.4	19.2	%

(a) Represents product and service revenue between reportable segments.

Scientific Instruments Segment Revenues

Scientific Instruments segment revenue increased by $43.6 million, or 18.1%, to $284.9 million for the three months ended June 30, 2010, compared to $241.3 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $4.6 million from the impact of foreign exchange due to the strengthening of the U.S. Dollar versus the Euro and other foreign currencies and an increase of approximately $3.7 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $44.5 million, or 18.4%. The increase in revenue, excluding the effect of foreign exchange and acquisition, reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. The mix of products sold in the Scientific Instruments segment reflects increased demand from academic, government and industrial customers. We attribute the increase in spending by academic and government customers to new product introductions over the last twelve to eighteen months and stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. We also continued to benefit from improvements in the industrial markets that we serve.

System revenue and aftermarket revenue as a percentage of total Scientific Instruments segment revenue were as follows during the three months ended June 30, 2010 and 2009 (dollars in millions):

	Three Months Ended June 30,
	2010				2009
	Revenue		Percentage of Segment Revenue		Revenue		Percentage of Segment Revenue
System revenue	$	231.5	81.3	%	$	191.3	79.3	%
Aftermarket revenue	53.4		18.7	%	50.0		20.7	%
Total revenue	$	284.9	100.0	%	$	241.3	100.0	%

System revenues in the Scientific Instruments segment include X-ray systems, optical emission spectroscopy systems, atomic force microscopy systems, nuclear magnetic resonance systems, magnetic resonance imaging systems, electron paramagnetic imaging systems, mass spectrometry systems, CBRNE detection systems and molecular spectroscopy systems. Aftermarket revenues in the Scientific Instruments segment include accessory sales, consumables, training and services.

Energy & Supercon Technologies Segment Revenues

Energy & Supercon Technologies segment revenue increased by $4.4 million, or 32.1%, to $18.1 million for the three months ended June 30, 2010, compared to $13.7 million for the comparable period in 2009. Included in this change in revenue is a decrease of approximately $1.2 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 40.9%. The increase in revenue was the result of higher demand for low temperature superconducting wire.

System and wire revenue and aftermarket revenue as a percentage of total Energy & Supercon Technologies segment revenue were as follows during the three months ended June 30, 2010 and 2009 (dollars in millions):

Table of Contents

	Three Months Ended June 30,
	2010				2009
	Revenue		Percentage of Segment Revenue		Revenue		Percentage of Segment Revenue
System and wire revenue	$	17.6	97.2	%	$	13.3	97.1	%
Aftermarket revenue	0.5		2.8	%	0.4		2.9	%
Total revenue	$	18.1	100.0	%	$	13.7	100.0	%

System and wire revenues in the Energy & Supercon Technologies segment include low and high temperature superconducting wire and superconducting devices, including magnets, linear accelerators and radio frequency cavities. Aftermarket revenues in the Energy & Supercon Technologies segment include accessory sales.

Income (Loss) from Operations

The following table presents income (loss) from operations and operating margins on revenue by reportable segment for the three months ended June 30, 2010 and 2009 (dollars in millions):

	Three Months Ended June 30,
	2010					2009
	Operating Income (Loss)			Percentage of Segment Revenue		Operating Income (Loss)			Percentage of Segment Revenue
Scientific Instruments	$	40.4		14.2	%	$	20.4		8.5	%
Energy & Supercon Technologies	(1.7		)	(9.4	)%	(0.7		)	(5.1	)%
Corporate, eliminations and other (a)	(0.8		)			0.5
Total operating income	$	37.9		12.6	%	$	20.2		8.0	%

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

Scientific Instruments segment income from operations for the three months ended June 30, 2010 was $40.4 million, resulting in an operating margin of 14.2%, compared to income from operations of $20.4 million, resulting in an operating margin of 8.5%, for the comparable period in 2009. Income from operations in the Scientific Instruments segment improved as a result of the higher revenues described above, an improvement in gross profit margins and a reduction in operating expenses as a percentage of revenue.

In the second quarter of 2010, gross profit margin as a percentage of revenue in the Scientific Instruments segment increased to 46.8% from 45.4% for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products and the weakening of the Euro, which favorably impacts our gross profit margins as a majority of our production is performed in Europe. The increase in revenue also allowed us to better utilize our production facilities and leverage our fixed production costs. We also reduced production costs through various cost saving initiatives.

In the second quarter of 2010, operating expenses, excluding other charges, in the Scientific Instruments increased to $91.1 million, or 32.0% of segment revenue, from $89.2 million, or 37.0% of segment revenue for the comparable period in 2009. This increase is a function of incremental investments in sales and marketing activities and research and development activities that we believe will generate future growth offset, in part, by changes in foreign currency exchange rates.

Energy & Supercon Technologies segment loss from operations for the three months ended June 30, 2010 was $1.7 million, resulting in an operating margin of (9.4)%, compared to a loss from operations of $0.7 million, resulting in an operating margin of (5.1)%, for the comparable period in 2009. The loss from operations in the second quarter of 2009

Table of Contents

included a bargain purchase gain of $2.1 million recorded in connection with the acquisition of the research instruments business from Varian Medical Systems, offset, in part, by $0.4 million of transaction costs incurred in connection with the acquisition of the research instruments business and $0.7 million of impairment charges associated with certain fixed assets used in the production of certain superconducting wire. Excluding the effects of these net credits, the loss from operations in the second quarter of 2009 was $1.7 million, resulting in an operating margin of (12.4)%. The improvement in operating loss, excluding the net credit described above is a function of higher revenues and an improvement in gross margins.

Six Months Ended June 30, 2010 compared to the Six Months Ended June 30, 2009

Consolidated Results

The following table presents our results for the six months ended June 30, 2010 and 2009 (dollars in millions, except per share data):

	Six Months Ended
	June 30,
	2010			2009
Product revenue	$	511.0		$	425.1
Service revenue	64.0			55.2
Other revenue	3.6			2.7
Total revenue	578.6			483.0

Cost of product revenue	283.3			236.9
Cost of service revenue	33.3			32.2
Total cost of revenue	316.6			269.1
Gross profit	262.0			213.9

Operating expenses:
Selling, general and administrative	129.7			118.9
Research and development	64.0			60.2
Amortization of acquisition-related intangible assets	1.1			0.9
Other charges (credits), net	2.4			(0.6		)
Total operating expenses	197.2			179.4
Operating income	64.8			34.5

Interest and other income (expense), net	(4.5		)	(2.8		)
Income before income taxes and noncontrolling interest in consolidated subsidiaries	60.3			31.7
Income tax provision	21.4			10.4
Consolidated net income	38.9			21.3
Net income attributable to noncontrolling interest in consolidated subsidiaries	0.2			—
Net income attributable to Bruker Corporation	$	38.7		$	21.3

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.24		$	0.13
Diluted	$	0.23		$	0.13

Weighted average common shares outstanding:
Basic	164.2			163.3
Diluted	165.7			164.5

Table of Contents

Revenue

For the six months ended June 30, 2010, our revenue increased by $95.6 million, or 19.8%, to $578.6 million, compared to $483.0 million for the comparable period in 2009. Included in this change in revenue are increases of approximately $12.8 million from the impact of foreign exchange due to the weakening of the U.S. Dollar versus the Euro and other foreign currencies and $10.5 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $72.3 million, or 15.0%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $63.7 million, or 13.7%, and the Energy & Supercon Technologies segment, which increased by $10.3 million, or 47.2%. Revenue in the Scientific Instruments segment reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. Revenues in the Energy & Supercon Technologies segment increased due to higher demand for low temperature superconducting wire.

The mix of products sold in the Scientific Instruments segment reflects increased demand from academic, government and industrial customers. We attribute the increase in sales of magnetic resonance and mass spectrometry products and spending by academic and government customers to our new product introductions over the last twelve to eighteen months and to stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. The improvement in revenues from our industrial customers continues to reflect an ongoing improvement in these markets. We remain optimistic that the industrial markets we serve will continue to improve but we will continue to monitor the recovery in these markets. We are also monitoring the developments in academic and government research budgets, primarily in Europe. While many European governments have announced their intentions to reduce overall spending, we believe that funding for the majority of our products and markets will remain stable, or grow in some cases, in most of our key European markets.

Cost of Revenue

Our cost of product and service revenue for the six months ended June 30, 2010, was $316.6 million, resulting in a gross profit margin of 45.3%, compared to cost of product and service revenue of $269.1 million, resulting in a gross profit margin of 44.3%, for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products. The increase in revenue also allowed us to better utilize our production facilities and leverage our fixed production costs. We also reduced production costs through various cost saving initiatives.

Selling, General and Administrative

Our selling, general and administrative expense for the six months ended June 30, 2010 increased to $129.7 million, or 22.4% of revenue, from $118.9 million, or 24.6% of revenue, for the comparable period in 2009. The increase in selling, general and administrative expense is attributable to increases in headcount in support of our revenue growth and acquisitions. The increase in selling, general and administrative expense is also partly attributable to changes in foreign currency exchange rates, primarily the Euro.

Research and Development

Our research and development expense for the six months ended June 30, 2010 increased to $64.0 million, or 11.1% of revenue, from $60.2 million, or 12.5% of revenue, for the comparable period in 2009. We continue to make incremental investments in research and development projects that we believe will generate future growth. The increase in research and development expense is also partly attributable to changes in foreign currency exchange rates, primarily the Euro, as a majority of our research and development is performed in Europe.

Amortization of Acquisition-Related Intangible Assets

Our amortization expense from acquisition-related intangible assets was $1.1 million for the six months ended June 30, 2010 compared with $0.9 million for the comparable period in 2009. The increase in amortization expense relates to intangible assets acquired in connection with the chemical analysis business from Agilent.

Other Charges (Credits), Net

Other charges (credits), net of $2.4 million in the first half of 2010 related entirely to the Scientific Instruments segment

Table of Contents

and include a loss of $1.0 million associated with the sale of our investment in Bruker Baltic Ltd., a manufacturing site located in Riga, Latvia that was engaged in the production of certain components used in our X-ray product lines. In addition, we incurred $0.2 million of restructuring charges, which related primarily to severance incurred in connection with closing a production facility in Herzogenrath, Germany. We incurred the loss on our investment and the restructuring charges as part of our broader corporate strategy of reducing costs and consolidating critical production and know-how in certain key production sites. In addition, other charges (credits), net in the first half of 2010 includes $0.7 million of acquisition-related costs and $0.5 million of transition-related costs incurred in connection with our acquisition of the chemical analysis business from Agilent.

Acquisition-related credits of $(0.6) million in the first half of 2009 relate entirely to the Energy and Supercon Technologies segment and include a bargain purchase gain of $2.1 million recorded in connection with the acquisition of the research instruments business from Varian Medical Systems, offset, in part, by $0.8 million of transaction costs incurred in connection with the acquisition of the research instruments business and $0.7 million of impairment charges associated with certain fixed assets used in the production of certain superconducting wire.

Interest and Other Income (Expense), Net

Interest and other income (expense), net during the six months ended June 30, 2010 was $(4.5) million, compared to $(2.8) million for the comparable period of 2009.

During the six months ended June 30, 2010, the major components within interest and other income (expense), net were net interest expense of $2.5 million and unrealized losses on foreign currency transactions of $1.9 million. During the six months ended June 30, 2009, the major components within interest and other income (expense), net were net interest expense of $3.6 million offset, in part, by realized and unrealized gains on foreign currency transactions of $0.6 million.

The decrease in interest expense is a function of lower outstanding debt, as we reduced our total debt by $11.0 million in the first half of 2010. Losses on foreign currency exchange rates in the first half of 2010 were primarily a function of changes in exchange rates between the Euro and the Swiss Franc.

Income Tax Provision

The income tax provision for the six months ended June 30, 2010, was $21.4 million compared to $10.4 million for the six months ended June 30, 2009, representing effective tax rates of 35.5% and 32.8%, respectively. This change in our effective tax rate relates primarily to the amount and mix of income and taxes outside of the U.S.

Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests for the six months ended June 30, 2010 was $0.2 million compared to $0.0 million for the comparable period of 2009. Net income attributable to noncontrolling interests represents the minority shareholders’ proportionate share of the net income recorded by five majority-owned indirect subsidiaries, Bruker Baltic Ltd., Bruker Labmate Pvt. Ltd., InCoaTec GmbH and Perch Solutions OY, which are included in the Scientific Instruments segment, and RI Research Instruments GmbH, which is included in the Energy & Supercon Technologies segment.

Net Income Attributable to Bruker Corporation

Our net income for the six months ended June 30, 2010, was $38.7 million, or $0.23 per diluted share, compared to $21.3 million, or $0.13 per diluted share for the comparable period in 2009.

Table of Contents

Segment Results

Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment for the six months ended June 30, 2010 and 2009 (dollars in millions):

	Six Months Ended June 30,						Dollar			Percentage
	2010			2009			Change			Change
Scientific Instruments	$	545.2		$	464.9		$	80.3		17.3	%
Energy & Supercon Technologies	38.8			21.8			17.0			78.0	%
Eliminations (a)	(5.4		)	(3.7		)	(1.7		)
	$	578.6		$	483.0		$	95.6		19.8	%

(a) Represents product and service revenue between reportable segments.

Scientific Instruments Segment Revenues

Scientific Instruments segment revenue increased by $80.3 million, or 17.3%, to $545.2 million for the six months ended June 30, 2010, compared to $464.9 million for the comparable period in 2009. Included in this change in revenue is an increase of approximately $12.9 million from the impact of foreign exchange due to the strengthening of the U.S. Dollar versus the Euro and other foreign currencies and an increase of approximately $3.7 million attributable to acquisition. Excluding the effect of foreign exchange and acquisition, revenue increased by $63.7 million, or 13.7%. The increase in revenue, excluding the effect of foreign exchange and acquisition, reflects an increase in sales of all of our core technologies, particularly in magnetic resonance, X-ray and mass spectrometry. The mix of products sold in the Scientific Instruments segment reflects increased demand from academic, government and industrial customers. We attribute the increase in spending by academic and government customers to new product introductions over the last twelve to eighteen months and stimulus packages implemented by governments of various countries, including the U.S., Germany, Japan and China. We also continued to benefit from improvements in the industrial markets that we serve.

System revenue and aftermarket revenue as a percentage of total Scientific Instruments segment revenue were as follows during the six months ended June 30, 2010 and 2009 (dollars in millions):

	Six Months Ended June 30,
	2010				2009
	Revenue		Percentage of Segment Revenue		Revenue		Percentage of Segment Revenue
System revenue	$	437.9	80.3	%	$	367.8	79.1	%
Aftermarket revenue	107.3		19.7	%	97.1		20.9	%
Total revenue	$	545.2	100.0	%	$	464.9	100.0	%

Energy & Supercon Technologies Segment Revenues

Energy & Supercon Technologies segment revenue increased by $17.0 million, or 78.0%, to $38.8 million for the six months ended June 30, 2010, compared to $21.8 million for the comparable period in 2009. Included in this change in revenue is an increase of $6.8 million attributable to the research instruments business we acquired from Varian Medical Systems and a decrease of approximately $0.1 million from the impact of foreign exchange. Excluding the effect of acquisition and foreign exchange, revenue increased by $10.3 million, or 47.2%. The increase in revenue was the result of higher demand for low temperature superconducting wire.

Table of Contents

System and wire revenue and aftermarket revenue as a percentage of total Energy & Supercon Technologies segment revenue were as follows during the six months ended June 30, 2010 and 2009 (dollars in millions):

	Six Months Ended June 30,
	2010				2009
	Revenue		Percentage of Segment Revenue		Revenue		Percentage of Segment Revenue
System and wire revenue	$	37.4	96.4	%	$	20.9	95.9	%
Aftermarket revenue	1.4		3.6	%	0.9		4.1	%
Total revenue	$	38.8	100.0	%	$	21.8	100.0	%

Income (Loss) from Operations

The following table presents income (loss) from operations and operating margins on revenue by reportable segment for the six months ended June 30, 2010 and 2009 (dollars in millions):

	Six Months Ended June 30,
	2010					2009
	Operating Income (Loss)			Percentage of Segment Revenue		Operating Income (Loss)			Percentage of Segment Revenue
Scientific Instruments	$	68.1		12.5	%	$	36.5		7.9	%
Energy & Supercon Technologies	(2.2		)	(5.7	)%	(3.1		)	(14.2	)%
Corporate, eliminations and other (a)	(1.1		)			1.1
Total operating income	$	64.8		11.2	%	$	34.5		7.1	%

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

Scientific Instruments segment income from operations for the six months ended June 30, 2010 was $68.1 million, resulting in an operating margin of 12.5%, compared to income from operations of $36.5 million, resulting in an operating margin of 7.9%, for the comparable period in 2009. Income from operations in the Scientific Instruments segment improved as a result of the higher revenues described above and an improvement in gross profit margins and a reduction in operating expenses as a percentage of revenue.

In the first half of 2010, gross profit margin as a percentage of revenue in the Scientific Instruments segment increased to 46.9% from 45.4% for the comparable period in 2009. Higher gross profit margins resulted primarily from changes in product mix, specifically an increase in revenues from high-end instrumentation, including our newly introduced products which were designed to carry higher gross margins than our previous generations of products. The increase in revenue also allowed us to better utilize our production facilities and leverage our fixed production costs. We also reduced production costs through various cost saving initiatives.

In the first half of 2010, operating expenses, excluding other charges, in the Scientific Instruments increased to $185.4 million, or 34.0% of segment revenue, from $174.5 million, or 37.5% of segment revenue for the comparable period in 2009. This increase is a function of incremental investments in sales and marketing activities and research and development activities that we believe will generate future growth. To a lesser degree, changes in foreign currency exchange rates contributed to the increase in operating expenses.

Energy & Supercon Technologies segment loss from operations for the six months ended June 30, 2010 was $2.2 million,

Table of Contents

resulting in an operating margin of (5.7)%, compared to a loss from operations of $3.1 million, resulting in an operating margin of (14.2)%, for the comparable period in 2009. The loss from operations in the first half of 2009 included a bargain purchase gain of $2.1 million recorded in connection with the acquisition of the research instruments business from Varian Medical Systems, offset, in part, by $0.8 million of transaction costs incurred in connection with the acquisition of the research instruments business and $0.7 million of impairment charges associated with certain fixed assets used in the production of certain superconducting wire. Excluding the effects of these net credits, the loss from operations in the first half of 2009 was $3.7 million, resulting in an operating margin of (17.0)%. The improvement in operating loss, excluding the net credit described above is a function of higher revenues and an improvement in gross margins.

LIQUIDITY AND CAPITAL RESOURCES

We currently anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months, but this depends on our profitability and our ability to manage working capital requirements. Our future cash requirements will also be affected by acquisitions that we may make in the future. Historically, we have financed our growth through cash flow generation and a combination of debt financings and issuances of common stock. In the future, there are no assurances that additional financing alternatives will be available to us if required, or if available, will be obtained on terms favorable to us.

During the six months ended June 30, 2010, net cash provided by operating activities was $53.1 million, resulting primarily from $51.9 million of consolidated net income adjusted for non-cash items and $1.2 million of net changes in working capital. During the six months ended June 30, 2009, net cash provided by operating activities was $51.3 million, resulting primarily from $34.8 million of net income adjusted for non-cash items and $16.5 million of net changes in working capital.

During the six months ended June 30, 2010, net cash used by investing activities was $48.5 million, compared to net cash used by investing activities of $8.2 million during the six months ended June 30, 2009. Cash used by investing activities during the six months ended June 30, 2010 was attributable to $37.8 million used for acquisitions and $10.7 million of capital expenditures. Cash used by investing activities during the six months ended June 30, 2009 was attributable to $7.1 million of capital expenditures and $1.1 million used for acquisitions. Capital expenditures during the six months ended June 30, 2010 were at a level consistent with our planned capital spending of $20.0 million to $30.0 million in 2010.

During the six months ended June 30, 2010, net cash used by financing activities was $8.9 million, compared to net cash used by financing activities of $52.1 million during the six months ended June 30, 2009. Cash used by financing activities during the six months ended June 30, 2010 and June 30, 2009 was primarily attributable to $10.3 million and $51.7 million, respectively, of net debt repayments under various long-term and short-term arrangements.

At June 30, 2010, we had outstanding debt totaling $126.7 million consisting of $121.9 million outstanding under the term loan component of the Credit Agreement and $4.8 million under capital lease obligations. At December 31, 2009, we had outstanding debt totaling $137.7 million consisting of $131.3 million outstanding under the term loan component of the Credit Agreement, $0.3 million outstanding under other long-term debt arrangements, $0.1 million outstanding under other revolving lines of credit and $6.0 million under capital lease obligations.

In February 2008, we entered into a credit agreement with a syndication of lenders, which we refer to as the Credit Agreement. The Credit Agreement provides a revolving credit line with a maximum commitment of $230.0 million and a term loan facility of $150.0 million. The outstanding principal and interest under the term loan is payable in quarterly installments through December 2012. Borrowings under the Credit Agreement bear interest, at our option, at either (i) the higher of the prime rate or the federal funds rate plus 0.50%, or (ii) adjusted LIBOR, plus margins ranging from 0.40% to 1.25% and a facility fee ranging from 0.10% to 0.20%. As of June 30, 2010, the weighted average interest rate of borrowings under the term facility of the Credit Agreement was approximately 2.7%.

Borrowings under the Credit Agreement are secured by the pledge to the banks of 100% of the capital stock of each of our wholly-owned domestic subsidiaries and 65% of the capital stock of certain of our wholly-owned direct or indirect foreign subsidiaries. The Credit Agreement also requires that we maintain certain financial ratios related to maximum leverage and minimum interest coverage, as defined in the Credit Agreement. Specifically, our leverage ratio cannot exceed 3.0 and our interest coverage ratio cannot be less than 3.0. In addition to the financial ratios, the Credit Agreement restricts, among other

Table of Contents

things, our ability to do the following: make certain payments; incur additional debt; incur certain liens; make certain investments, including derivative agreements; merge, consolidate, sell or transfer all or substantially all of our assets; and enter into certain transactions with affiliates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. As of June 30, 2010, the latest measurement date, we were in compliance with the covenants of the Credit Agreement.

In addition to revolving loans under the Credit Agreement, we have other revolving loans with various financial institutions located primarily in Germany, Switzerland and France. The following is a summary of the maximum commitments and net amounts available to the Company under revolving loans as of June 30, 2010 (in millions):

	Weighted Average Interest Rate		Total Amount Committed by Lenders		Outstanding Borrowings		Outstanding Letters of Credit		Total Amount Available
Credit Agreement	—	%	$	230.0	$	—	$	1.4	$	228.6
Other revolving loans	—	%	90.7		—		76.5		14.2
Total revolving loans			$	320.7	$	—	$	77.9	$	242.8

As of June 30, 2010, we had approximately $4.1 million of net operating loss carryforwards available to reduce future U.S. taxable income. However, these losses are severely limited in terms of their use. The Company also has approximately $49.0 million of German Trade Tax net operating losses that are carried forward indefinitely and U.S. tax credits of approximately $4.4 million available to offset future tax liabilities that expire at various dates. U.S. tax credits, after the filing of the 2008 U.S. Federal tax return in September 2009, include foreign tax credits of $2.5 million expiring in various years through 2019 and research and development tax credits of $1.8 million expiring at various dates through 2025 and other credits of $0.1 million. These operating losses and tax credit carryforwards may be subject to limitations under provisions of the Internal Revenue Code.

The following table summarizes maturities for our significant financial obligations as of June 30, 2010 (in millions):

Contractual Obligations	Total		Less than 1 Year		1-3 Years		4-5 Years		More than 5 Years
Long-term debt, including current portion	$	126.7	$	25.1	$	99.4	$	1.4	$	0.8
Derivative liabilities	8.8		6.5		2.3		—		—
Uncertain tax contingencies	24.3		—		24.3		—		—

Uncertain tax contingencies are positions taken or expected to be taken on an income tax return that may result in additional payments to tax authorities. The total amount of uncertain tax contingencies is included in the “1-3 Years” column as we are not able to reasonably estimate the timing of potential future payments. If a tax authority agrees with the tax position taken or expected to be taken or the applicable statute of limitations expires, then additional payments will not be necessary.

Nasdaq Compliance

Collin J. D’Silva, a former independent member of our Board of Directors and the Board’s Audit Committee, voluntarily resigned from service on the Audit Committee, effective March 9, 2010, and from service on the Board, effective March 31, 2010, in connection with joining the Company as President of the newly-formed Chemical Analysis Division of Bruker Daltonics. On March 24, 2010, we notified Nasdaq that due to the vacancy on our Audit Committee created by Mr. D’Silva’s resignation from the Audit Committee, we were no longer in compliance with Nasdaq Listing Rule 5605 (“Rule 5605”), which requires that the Audit Committee be comprised of at least three members, each of whom is independent. On March 25, 2010, we received notice from Nasdaq advising that, as a result of Mr. D’Silva’s resignation from the Audit Committee, we were not in compliance with Rule 5605 and confirming that we were provided a cure period until September 7, 2010 to regain compliance. Additionally, on April 1, 2010, we received notice from Nasdaq that, due to the resignation of Mr. D’Silva from our Board, we were not in compliance with the majority independent director requirements set forth in Rule 5605. Nasdaq provided a cure period until September 27, 2010 to regain compliance with the majority independence requirements. On August 2, 2010, our Board of Directors appointed Charles F. Wagner, Jr. as an independent director. Mr. Wagner has also

Table of Contents

become a member of the Board’s Audit Committee. With the appointment of Mr. Wagner to the Board of Directors and the Board’s Audit Committee, we are in compliance with the majority independent director requirements and the audit committee requirements in Rule 5605.

RECENT ACCOUNTING PRONOUNCEMENTS

In September 2009, the Emerging Issues Task Force, or EITF, reached consensus on FASB Accounting Standards Update 2009-14, Software (Topic 985)—Certain Revenue Arrangements That Include Software Elements . FASB Accounting Standards Updates 2009-14 changes the accounting model for revenue arrangements that include both tangible products and software elements. Under this guidance, tangible products containing software components and non-software components that function together to deliver the tangible product’s essential functionality are excluded from the software revenue guidance in Subtopic No. 985-605, Software-Revenue Recognition. In addition, hardware components of a tangible product containing software components are always excluded from the software revenue guidance. FASB Accounting Standards Updates 2009-14 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. However, early adoption is permitted. We are currently assessing the impact that this update will have on our results of operations and financial position and when we will adopt these requirements.

In September 2009, the EITF reached consensus on FASB Accounting Standards Update 2009-13, Revenue Recognition (Topic 605)—Multiple-Deliverable Revenue Arrangements . FASB Accounting Standards Update 2009-13 addresses the accounting for multiple-deliverable arrangements to enable vendors to account for products or services separately rather than as a combined unit. Specifically, this guidance amends the criteria in Subtopic No. 605-25, Revenue Recognition-Multiple-Element Arrangements, for separating consideration in multiple-deliverable arrangements. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence; (b) third-party evidence; or (c) estimates. This guidance also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. In addition, this guidance significantly expands required disclosures related to a vendor’s multiple-deliverable revenue arrangements. FASB Accounting Standards Update 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, however, early adoption is permitted. We are currently assessing the impact that this update will have on our results of operations and financial position and when we will adopt these requirements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks associated with changes in foreign exchange rates and interest rates. We selectively use financial instruments to reduce these risks. All transactions related to risk management techniques are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign exchange and interest rate risk include market valuations and sensitivity analysis.

Impact of Foreign Currencies

We generate a substantial portion of our revenues in international markets, principally Europe and Japan, which subjects our operations to the exposure of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. Our costs related to sales in foreign currencies are largely denominated in the same respective currencies, limiting our transaction risk exposure. However, for sales not denominated in U.S. Dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. Dollars, it will require more of the foreign currency to equal a specified amount of U.S. Dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. Dollars than we did before the rate increase went into effect. If we price our products in U.S. Dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. Dollar could result in our prices not being competitive in a market where business is transacted in the local currency.

Our net foreign exchange gains (losses), net were $(1.9) million and $0.6 million for the six months ended June 30, 2010 and 2009, respectively. From time to time, we enter into foreign currency contracts in order to minimize the volatility that fluctuations in exchange rates have on our cash flows related to purchases and sales denominated in foreign currencies. We will continue to evaluate our currency risks and in the future may utilize foreign currency contracts more frequently as part of a transactional hedging program.

Table of Contents

Impact of Interest Rates

We may invest excess cash in short-term investments that are subject to changes in interest rates. We believe that the market risk arising from holding these financial instruments is minimal.

Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates. Our objective in managing our exposure to interest rates is to decrease the volatility that changes in interest rates might have on our earnings and cash flows. To achieve this objective we entered into an interest rate swap. In April 2008, we entered into an interest rate swap arrangement to pay a fixed rate of approximately 3.8% and receive a variable rate based on three month LIBOR through December 31, 2012. The initial notional amount of this interest swap was $90.0 million and amortizes in proportion to the term debt component of our Credit Agreement. At June 30, 2010, the outstanding notional amount of this swap was $73.1 million. We have determined that this swap is an effective hedge of the variability of cash flows of the interest payments. At June 30, 2010, a 10% increase or decrease in the average cost of our outstanding variable rate debt would not result in a material change in pre-tax interest expense.

Inflation

We do not believe inflation had a material impact on our business or operating results during any of the periods presented.

ITEM 4. CONTROLS AND PROCEDURES

We have established disclosure controls and procedures that are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) by others within our organization. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2010. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, as of June 30, 2010, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2010 that materially affected, or are reasonably likely to affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Except as set forth below there have been no material changes to the legal proceedings disclosed in Part I, “Item 3. Legal Proceedings” in our Annual Report on Form 10-K for the year ended December 31, 2009 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.

As previously reported, in November 2008 a former employee of Bruker Corporation filed a complaint with the Massachusetts Commission Against Discrimination (“MCAD”) alleging age discrimination. The Company responded to an information request from the MCAD on April 23, 2010. The MCAD recently found probable cause in this matter and has scheduled a conciliation conference for November 1, 2010. The Company believes the complaint made by the former employee to be without merit and intends to defend the matter vigorously.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2009, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we

Table of Contents

currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

ITEM 2. UNREGISTERED SALE S OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPO N SENIOR SECURITIES

None.

ITEM 4. [REMOVED AND R ESERVED]

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit No.		Description
10.1		Bruker Corporation 2010 Incentive Compensation Plan Form of Incentive Stock Option Agreement(1)
10.2		Bruker Corporation 2010 Incentive Compensation Plan Form of Non-Qualified Stock Option Agreement(1)
10.3		Bruker Corporation 2010 Incentive Compensation Plan Form of Restricted Stock Agreement(1)
31.1		Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(1)
31.2		Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(1)
32.1		Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002(2)

(1) Filed herewith.

(2) Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BRUKER CORPORATION

Date: August 9, 2010	By:	/s/ FRANK H. LAUKIEN, PH.D.
		Frank H. Laukien, Ph.D. President, Chief Executive Officer and Chairman (Principal Executive Officer)

Date: August 9, 2010	By:	/s/ BRIAN P. MONAHAN
		Brian P. Monahan Chief Financial Officer (Principal Financial Officer)

Exhibit 10.1

BRUKER CORPORATION

FORM OF STOCK OPTION AGREEMENT

UNDER 2010 INCENTIVE COMPENSATION PLAN

INCENTIVE STOCK OPTION

AGREEMENT entered into [ ] by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company” ), and the undersigned employee (the “Employee”) of the Company or one of its subsidiaries (the Company and its subsidiaries herein together referred to as the “Company”).

1. The Company desires to grant the Employee an incentive stock option under the Company’s 2010 Incentive Compensation Plan (the “2010 Plan”) to acquire shares of the Company’s common stock, $.01 par value per share (the “Shares”).

2. Section 6 of the 2010 Plan provides that each option is to be evidenced by an option agreement, setting forth the terms and conditions of the option.

ACCORDINGLY, in consideration of the premises and of the mutual covenants and agreements contained herein, the Company and the Employee hereby agree as follows:

1. Grant of Option . The Company hereby irrevocably grants under the 2010 Plan and subject to the terms and conditions of the 2010 Plan to the Employee an incentive stock option (the “Option”) to purchase all or any part of an aggregate of [ ] Shares on the terms and conditions hereinafter set forth.

2. Purchase Price . The purchase price (“Purchase Price”) for the Shares covered by the Option shall be $[ ] per Share.

3. Time of Exercise of Option .

(a) The Option shall not be exercisable prior to one (1) year from grant. Thereafter, the Option shall only be exercisable as follows:

	Percentage of
	Shares Becoming		Cumulative
	Available for		Percentage
On or After	Exercise		Available

12 months	20	%	20	%
24 months	20	%	40	%
36 months	20	%	60	%
48 months	20	%	80	%
60 months	20	%	100	%

4. Term of Options; Exercisability .

(a) Each Option shall expire not more than ten (10) years from the date of the granting thereof, but shall be subject to earlier termination as herein provided.

(b) Except as otherwise provided in this Section 4, if the Employee ceases to be an employee of the Company, the Option granted to the Employee hereunder shall terminate on the date that

is sixty (60) days after the Employee ceases to be an employee of the Company, or on the date on which the Option expires by its terms, whichever occurs first, and the Option shall not be exercisable after such date.

(c) If such termination of employment is because the Employee has become permanently disabled (within the meaning of Section 22(e)(3) of the Internal Revenue Code of 1986, as amended (the “Code”)), such Option shall terminate sixty (60) days from the date the Employee ceases to be an employee, or on the date on which the Option expires by its terms, whichever occurs first.

(d) If such termination of employment is “for cause”, all outstanding and unexercised portions of the Option as of the time the Employee is notified that the Employee’s employment is terminated “for cause” will immediately be forfeited. For purposes of this Agreement, “cause” shall include (and is not limited to) dishonesty with respect to the Company or any of its affiliates, breach of fiduciary duty, insubordination, substantial malfeasance or non-feasance of duty, unauthorized disclosure of confidential information, material failure or refusal to comply with Company’s published policies generally applicable to all employees, and conduct materially harmful to the business of the Company or any of its affiliates. The determination of the Compensation Committee (as defined in the 2010 Plan) as to the existence of “cause” will be conclusive on the Employee and the Company. In addition, “cause” is not limited to events which have occurred prior to the Employee’s termination of employment, nor is it necessary that the Compensation Committee’s finding of “cause” occur prior to termination. If the Compensation Committee determines, subsequent to the Employee’s termination of employment but prior to the exercise of the Option, or any portion thereof, that either prior or subsequent to the Employee’s termination the Employee engaged in conduct which would constitute “cause”, then the right to exercise any outstanding unexercised portion of the Option will be immediately forfeited. Notwithstanding the foregoing, any definition in an agreement between the Employee and the Company which (i) contains a conflicting definition of “cause” for termination and (ii) is in effect at the time of such termination shall supersede the definition in this Agreement with respect to the Employee.

(e) In the event of the death of the Employee, the Option granted to the Employee shall terminate ninety (90) days from the date of death, or on the date on which the Option expires by its terms, whichever occurs first.

(f) If the Employees ceases to be an employee of the Company, the Option shall be exercisable only to the extent that the right to purchase Shares under such Option, as provided in Section 3, has accrued and is in effect on the date of termination of employment.

(g) No partial exercise may be made for less than fifty (50) full Shares.

(h) In the event of the death of the Employee, the Option may be exercised by the estate of the Employee, or by any person or persons who acquired the right to exercise the Option by will or pursuant to the laws of descent and distribution as a result of the death of the Employee, subject to Section 4(d) hereof.

5. Manner of Exercise of Option .

with a copy of irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds to pay the exercise price, (d) at the discretion of the Compensation Committee, by a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise by the largest whole number of Shares with a fair market value that does not exceed the aggregate exercise price, together with cash or other payment from the Employee to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole Shares, or (e) at the discretion of the Compensation Committee, by any combination of (a), (b), (c) and (d) above. Upon such exercise, delivery of a certificate for paid-up, non-assessable Shares shall be made at the principal office of the Company to the person exercising the Option, not more than thirty (30) days from the date of receipt of the notice by the Company.

(b) The Company shall at all times during the term of the Option reserve and keep available such number of Shares of its common stock as will be sufficient to satisfy the requirements of the Option. The Employee shall not have any of the rights of a stockholder of the Company in respect of the Shares until one or more certificates for such Shares shall be delivered to him or her upon the due exercise of the Option.

6. Non-Transferability . The right of the Employee to exercise the Option shall not be assignable or transferable by the Employee otherwise than by will or the laws of descent and distribution, and the Option may be exercised during the lifetime of the Employee only by him or her. The Option shall be null and void and without effect upon the bankruptcy of the Employee or upon any attempted assignment or transfer, except as hereinabove provided, including without limitation any purported assignment, whether voluntary or by operation of law, pledge, hypothecation or other disposition contrary to the provisions hereof, or levy of execution, attachment, divorce, trustee process or similar process, whether legal or equitable, upon the Option.

7. (a) Representation Letter and Investment Legend .

(i) In the event that for any reason the Shares to be issued upon exercise of the Option shall not be effectively registered under the Securities Act of 1933, upon any date on which the Option is exercised in whole or in part, the person exercising the Option shall give a written representation to the Company in the form attached hereto as Exhibit 1 and the Company shall place an “investment legend”, so-called, as described in Exhibit 1 , upon any certificate for the Shares issued by reason of such exercise.

(ii) The Company shall be under no obligation to qualify Shares or to cause a registration statement or a post-effective amendment to any registration statement to be prepared for the purpose of covering the issue of Shares.

(b) Holding of Incentive Stock Option Shares; Legend . In order to enable the Company to determine when it is entitled to a tax deduction upon the disposition of any Shares issued upon exercise of this Option, for the periods during which such a disposition would entitle the Company to such a deduction (generally, a disposition within two years from the date of grant of the Option or within one year from the date of exercise of the Option will entitle the Company to a deduction), all stock certificates of such Shares shall be held by the Employee in his or her name and not in the name of a broker, nominee or other person or entity, and shall bear a legend reflecting that such Shares were obtained upon exercise of an incentive stock option. The Employee acknowledges that the Company may send a Form W-2, W-2c or substitute therefor, as appropriate, to the Employee with respect to any income recognized by the Employee upon a disposition of the Shares for the periods during which such a disposition would entitle the Company to such a deduction. Nothing in this Section 7(b) shall restrict the Employee from selling, transferring or otherwise disposing of such Shares at any time, but only from holding such Shares in other than his or her own name.

8. Adjustments on Changes in Recapitalization, Reorganization and the Like . Adjustments on changes in recapitalization, reorganization and the like shall be made in accordance with Section 13 of the 2010 Plan, as in effect on the date of this Agreement.

9. No Special Employment Rights . Nothing contained in the 2010 Plan or this Agreement shall be construed or deemed by any person under any circumstances to bind the Company to continue the employment of the Employee for the period within which this Option may be exercised.

10. Rights as a Shareholder . The Employee shall have no rights as a shareholder with respect to any Shares which may be purchased by exercise of this Option unless and until a certificate or certificates representing such Shares are duly issued and delivered to the Employee. Except as otherwise expressly provided in the 2010 Plan, no adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued.

ll. Withholding Taxes . Whenever Shares are to be issued upon exercise of this Option, the Company shall have the right to require the Employee to remit to the Company an amount sufficient to satisfy all Federal, foreign, state and local withholding tax requirements prior to issuance of the Shares and the delivery of any certificate or certificates for such Shares.

12. Qualification under Section 422 . It is understood and intended that the Option granted hereunder shall qualify as an “incentive stock option” as defined in Section 422 of the Code. Accordingly, the Employee understands that in order for the Employee to obtain the benefits of an incentive stock option under Section 421 of the Code, no sale or other disposition may be made of any Shares acquired upon exercise of the Option within the one-year period beginning on the day after the day of the transfer of such Shares to him or her, nor within the two-year period beginning on the day after the grant of the Option. If the Employee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any such Shares within said periods, he or she will notify the Company within thirty (30) days after such disposition.

13. Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts.

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed and its corporate seal to be hereto affixed by its officer thereunto duly authorized, and the Employee has hereunto set his or her hand and seal, all as of the day and year first above written.

EMPLOYEE				BRUKER CORPORATION


				By:

Name:				Title:

Address:

EXHIBIT 1

TO STOCK OPTION AGREEMENT

Ladies and Gentlemen:

In connection with the exercise by me as to [ ] shares of common stock, par value $.01 per share, of Bruker Corporation (the “Company”) under the incentive stock option dated [ ] granted to me under the 2010 Incentive Compensation Plan, I hereby acknowledge that I have been informed as follows:

1. The shares of common stock of the Company to be issued to me pursuant to the exercise of said option have not been registered under the Securities Act of 1933, as amended (the “Act”), and accordingly, must be held indefinitely unless such shares are subsequently registered under the Act, or an exemption from such registration is available.

2. Routine sales of securities made in reliance upon Rule 144 under the Act can be made only after the holding period and in limited amounts in accordance with the terms and conditions provided by that Rule, and in any sale to which that Rule is not applicable, registration or compliance with some other exemption under the Act will be required.

3. The Company is under no obligation to me to register the shares or to comply with any such exemptions under the Act.

4. The availability of Rule 144 is dependent in certain cases upon adequate current public information with respect to the Company being available and, at the time that I may desire to make a sale pursuant to the Rule, the Company may neither wish nor be able to comply with such requirement.

In consideration of the issuance of certificates for the shares to me, I hereby represent and warrant that I am acquiring such shares for my own account for investment, and that I will not sell, pledge or transfer such shares in the absence of an effective registration statement covering the same, except as permitted by the provisions of Rule 144, if applicable, or some other applicable exemption under the Act. In view of this representation and warranty, I agree that there may be affixed to the certificates for the shares to be issued to me, and to all certificates issued hereafter representing such shares (until in the opinion of counsel, which opinion must be reasonably satisfactory in form and substance to counsel for the Company, it is no longer necessary or required) a legend, as follows:

“The shares of common stock represented by this certificate have not been registered under the Federal Securities Act of 1933, as amended, and were acquired by the registered holder pursuant to a representation and warranty that such holder was acquiring such shares for his own account and for investment, with no intention to transfer or dispose of the same, in violation of the registration requirements of that Act. These shares may not be sold, pledged or transferred in the absence of an effective registration statement under the Securities Act of 1933, as amended, or an opinion of counsel, which opinion is reasonably satisfactory to counsel to the Company, to the effect that registration is not required under said Act.

In the event that the shares of common stock represented by this certificate are transferred within the two year period commencing on the date of this certificate, contemporaneous notice of such transfer must be provided to the Company.”

I further agree that the Company may place a stop order with its Transfer Agent, prohibiting the transfer of such shares, so long as the legend remains on the certificates representing the shares.

Very truly yours,

Exhibit 10.2

BRUKER CORPORATION

FORM OF STOCK OPTION AGREEMENT

UNDER 2010 INCENTIVE COMPENSATION PLAN

NON-QUALIFIED STOCK OPTION

AGREEMENT entered into [ ] by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company”), and the undersigned (the “Participant”) employee, officer, director, consultant or advisor of the Company or one of its subsidiaries (the Company and its subsidiaries herein together referred to as the “Company”).

1. The Company desires to grant the Participant a non-qualified stock option under the Company’s 2010 Incentive Compensation Plan (the “2010 Plan”) to acquire shares of the Company’s common stock, $.01 par value per share (the “Shares”).

2. Section 6 of the 2010 Plan provides that each option is to be evidenced by an option agreement, setting forth the terms and conditions of the option.

ACCORDINGLY, in consideration of the premises and of the mutual covenants and agreements contained herein, the Company and the Participant hereby agree as follows:

1. Grant of Option . The Company hereby irrevocably grants under the 2010 Plan and subject to the terms and conditions of the 2010 Plan to the Participant a non-qualified stock option (the “Option”) to purchase all or any part of an aggregate of [ ] Shares on the terms and conditions hereinafter set forth. This option shall not be treated as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”).

2. Purchase Price . The purchase price (“Purchase Price”) for the Shares covered by the Option shall be $[ ] per Share.

3. Time of Exercise of Option .

(a) The Option shall not be exercisable prior to one (1) year from grant. Thereafter, the Option shall only be exercisable as follows:

	Percentage of
	Shares Becoming		Cumulative
	Available for		Percentage
On or After	Exercise		Available
12 months	20	%	20	%
24 months	20	%	40	%
36 months	20	%	60	%
48 months	20	%	80	%
60 months	20	%	100	%

4. Term of Options; Exercisability .

(a) Term .

(1) Each Option shall expire not more than ten (10) years from the date of the granting thereof, but shall be subject to earlier termination as herein provided.

(2) Except as otherwise provided in this Section 4, if the Participant ceases to have the same relationship with the Company which was in existence on the date the Option was granted, the Option granted to the Participant hereunder shall terminate on the date that is sixty (60) days after the Participant ceases to have such relationship with the Company, or on the date on which the Option expires by its terms, whichever occurs first, and such Option shall not be exercisable after such date.

(3) If such termination of relationship is because the Participant has become permanently disabled (within the meaning of Section 22(e)(3) of the Code), the Option shall terminate sixty (60) days from the date the Participant ceases to be a Participant, or on the date on which the Option expires by its terms, whichever occurs first.

(4) If the relationship of the Participant with the Company is terminated “for cause”, all outstanding and unexercised portions of the Option as of the time the Participant is notified that the Participant’s service is terminated “for cause” will immediately be forfeited. For purposes of this Agreement, “cause” shall include (and is not limited to) dishonesty with respect to the Company or any of its affiliates, breach of fiduciary duty, insubordination, substantial malfeasance or non-feasance of duty, unauthorized disclosure of confidential information, material failure or refusal to comply with Company’s published policies generally applicable to all employees, and conduct materially harmful to the business of the Company or any of its affiliates. The determination of the Compensation Committee (as defined in the 2010 Plan) as to the existence of “cause” will be conclusive on the Participant and the Company. In addition, “cause” is not limited to events which have occurred prior to the Participant’s termination of service, nor is it necessary that the Compensation Committee’s finding of “cause” occur prior to termination. If the Compensation Committee determines, subsequent to the Participant’s termination of service but prior to the exercise of the Option, or any portion thereof, that either prior or subsequent to the Participant’s termination the Participant engaged in conduct which would constitute “cause”, then the right to exercise any outstanding unexercised portion of the Option will be immediately forfeited. Notwithstanding the foregoing, any definition in an agreement between the Participant and the Company which (i) contains a conflicting definition of “cause” for termination and (ii) is in effect at the time of such termination shall supersede the definition in this Agreement with respect to the Participant.

(5) In the event of the death of the Participant, the Option granted to the Participant shall terminate ninety (90) days from the date of death, or on the date on which the Option expires by its terms, whichever occurs first.

(b) Exercisability .

(1) If the Participant ceases to have the same relationship with the Company which was in existence on the date the Option was granted, the Option granted to the Participant hereunder shall be exercisable only to the extent that the right to purchase Shares under such Option has accrued and is in effect on the date such Participant ceases to have such relationship with the Company.

(2) No partial exercise may be made for less than fifty (50) full Shares.

(3) In the event of the death of the Participant, the Option granted to such Participant may be exercised by the estate of such Participant, or by any person or persons who acquired the right to exercise such Option by bequest or inheritance or by reason of the death of such Participant.

5. Manner of Exercise of Option .

(a) To the extent that the right to exercise the Option has accrued and is in effect, the Option may be exercised in full or in part by giving written notice to the Company stating the number of Shares exercised and accompanied by payment in full for such Shares. Payment shall be made (a) in cash or by check payable to the order of the Company, (b) at the discretion of the Compensation Committee, and so long as there is no adverse tax or accounting impact to the Company, by delivery of Shares owned by the Participant having a fair market value equal in amount to the exercise price of the Option being exercised and having been held by the Participant for at least six months, (c) at the discretion of the Compensation Committee, by delivery of a properly executed exercise notice to the Company, together with a copy of irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds to pay the exercise price, (d) at the discretion of the Compensation Committee, by a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise by the largest whole number of Shares with a fair market value that does not exceed the aggregate exercise price, together with cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole Shares, or (e) at the discretion of the Compensation Committee, by any combination of (a), (b), (c) and (d) above. Upon such exercise, delivery of a certificate for paid-up, non-assessable Shares shall be made at the principal office of the Company to the person exercising the Option, not more than thirty (30) days from the date of receipt of the notice by the Company.

(b) The Company shall at all times during the term of the Option reserve and keep available such number of Shares of its common stock as will be sufficient to satisfy the requirements of the Option. The Participant shall not have any of the rights of a stockholder of the Company in respect of the Shares until one or more certificates for such Shares shall be delivered to him or her upon the due exercise of the Option.

6. Non-Transferability . The right of the Participant to exercise the Option shall not be assignable or transferable by the Participant otherwise than by will or the laws of descent and distribution, and the Option may be exercised during the lifetime of the Participant only by him or her. The Option shall be null and void and without effect upon the bankruptcy of the Participant or upon any attempted assignment or transfer, except as hereinabove provided, including without limitation any purported assignment, whether voluntary or by operation of law, pledge, hypothecation or other disposition contrary to the provisions hereof, or levy of execution, attachment, trustee process or similar process, whether legal or equitable, upon the Option.

7. Representation Letter and Investment Legend .

(a) In the event that for any reason the Shares to be issued upon exercise of the Option shall not be effectively registered under the Securities Act of 1933 (the “1933 Act”), upon any date on which the Option is exercised in whole or in part, the person exercising the Option shall give a written representation to the Company in the form attached hereto as Exhibit 1 and the Company shall place an “investment legend”, so-called, as described in Exhibit 1, upon any certificate for the Shares issued by reason of such exercise.

(b) The Company shall be under no obligation to qualify Shares or to cause a registration statement or a post-effective amendment to any registration statement to be prepared for the purposes of covering the issue of Shares.

8. Adjustments on Changes in Recapitalization, Reorganization and the Like . Adjustments on Changes in Recapitalization, Reorganization and the Like shall be made in accordance with Section 13 of the 2010 Plan, as in effect on the date of this Agreement.

9. No Special Rights . Nothing contained in the 2010 Plan or this Agreement shall be construed or deemed by any person under any circumstances to bind the Company to continue the employment or other relationship of the Participant for the period within which this Option may be exercised.

10. Rights as a Shareholder . The Participant shall have no rights as a shareholder with respect to any Shares which may be purchased by exercise of this Option unless and until a certificate or certificates representing such Shares are duly issued and delivered to the Participant. Except as otherwise expressly provided in the 2010 Plan, no adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued.

11. Withholding Taxes . Whenever Shares are to be issued upon exercise of this Option, the Company shall have the right to require the Participant to remit to the Company an amount sufficient to satisfy all Federal, foreign, state and local withholding tax requirements prior to the delivery of any certificate or certificates for such Shares.

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed and its corporate seal to be hereto affixed by its officer thereunto duly authorized, and the Participant has hereunto set his or her hand and seal, all as of the day and year first above written.

PARTICIPANT				BRUKER CORPORATION


				By:


Name:				Title

Address:

EXHIBIT 1

TO STOCK OPTION AGREEMENT

Ladies and Gentlemen:

In connection with the exercise by me as to [ ] shares of common stock, par value $.01 per share, of Bruker Corporation (the “Company”) under the non-qualified stock option dated [ ] , granted to me under the 2010 Incentive Compensation Plan, I hereby acknowledge that I have been informed as follows:

3. The Company is under no obligation to me to register the shares or to comply with any such exemptions under the Act.

“The shares of common stock represented by this certificate have not been registered under the Federal Securities Act of 1933, as amended, and were acquired by the registered holder, pursuant to a representation and warranty that such holder was acquiring such shares for his own account and for investment, with no intention to transfer or dispose of the same, in violation of the registration requirements of that Act. These shares may not be sold, pledged, or transferred in the absence of an effective registration statement under the Securities Act of 1933, as amended, or an opinion of

counsel, which opinion is reasonably satisfactory to counsel to the Company, to the effect that registration is not required under said Act.”

I further agree that the Company may place a stop order with its Transfer Agent, prohibiting the transfer of such shares, so long as the legend remains on the certificates representing the shares.

Very truly yours,

Exhibit 10.3

FORM OF RESTRICTED STOCK AWARD AND AGREEMENT

AGREEMENT entered into this day of , 201X by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “ Company ”), and the undersigned (the “ Participant ”) employee, director, consultant or advisor of the Company or one of its subsidiaries (the Company and its subsidiaries herein together referred to as the “ Company ”).

WITNESSETH:

WHEREAS, the Company has granted to the Participant and the Participant has this day received from the Company [ ] shares of the Company’s common stock, par value $.01 per share (the “ Shares ”), pursuant to the Company’s 2010 Incentive Compensation Plan (the “ 2010 Plan ”); and

WHEREAS, a condition to the grant of the Shares to the Participant is that the Participant execute this Agreement;

NOW, THEREFORE, in consideration of the foregoing, the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. Forfeiture of Shares Upon Termination of Employment . Shares that do not become vested in accordance with the vesting criteria set forth in Section 2 (and any dividends or other distributions related to such Shares) shall be forfeited to the Company. Accordingly, if the Participant’s employment with the Company terminates for any reason, then all unvested Shares shall be automatically forfeited as of the date of termination, and any rights, including, without limitation, any voting or dividend rights, with respect to such forfeited Shares will immediately cease.

2. Vesting of Shares . So long as the Participant (a) continues to remain as an employee or director of the Company or (b) continues to provide significant services to the Company as a consultant or advisor, the Shares will be deemed to become “ Vested Shares ” twenty percent (20%) on each of the first five (5) anniversaries of the date of this Agreement. The foregoing vesting schedule notwithstanding, if the employment, directorship or other business relationship of the Participant with the Company, as applicable, terminates by reason of the Participant’s permanent and total disability (within the meaning of Section 22(e)(3) of the Internal Revenue Code) or death, all Shares or portions thereof not yet vested shall become immediately vested.

3. Restrictions on Transfers . Other than as set forth herein, Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively “transfer”), any of the Shares, or any interest therein, unless and until such Shares are Vested Shares.

4. Specific Enforcement . The Participant expressly acknowledges that the Company may be irreparably damaged if this Agreement is not specifically enforced. Upon a breach or threatened breach of the terms, covenants or conditions of this Agreement by Participant, the Company shall, in addition to all other remedies, be entitled to apply for a temporary or permanent injunction, or a decree for specific performance, in accordance with the provisions hereof.

5. Legend . Each certificate evidencing any of the Shares shall bear a legend substantially as follows:

“Any sale, assignment, transfer or other disposition of, or the voting of, the shares represented by this certificate is restricted by, and subject to, the terms and provisions of a certain Restricted Stock Award and Agreement dated as of . A copy of said Agreement is on file with the Secretary of the Corporation.”

6. Notices . Notices given hereunder shall be deemed to have been duly given on the date of personal delivery or on the date of postmark if mailed by certified or registered mail, return receipt requested, to the party being notified at his, her or its address specified on the signature page hereto or such other address as the addressee may subsequently notify the other parties of in writing.

7. Entire Agreement and Amendments . This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof and neither this Agreement nor any provision hereof may be waived, modified, amended or terminated except by a written agreement signed by the parties hereto. No waiver of any breach or default hereunder shall be considered valid unless in writing, and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature.

8. Governing Law; Successors and Assigns . This Agreement shall be governed by the internal laws of the State of Delaware without giving effect to the conflicts of laws principles thereof and, except as otherwise provided herein, shall be binding upon the heirs, personal representatives, executors, administrators, successors and assigns of the parties.

9. Severability . If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein.

10. Captions . Captions are for convenience only and are not deemed to be part of this Agreement.

11. Counterparts . This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, this Agreement has been executed as of the date and year first above written.

					BRUKER CORPORATION


By:					By:
Name:
Address:					Title:

EXHIBIT 31.1

CERTIFICATION

I, Frank H. Laukien, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bruker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2010	By:	/s/ FRANK H. LAUKIEN, PH.D.
		Frank H. Laukien, Ph.D. President, Chief Executive Officer and Chairman (Principal Executive Officer)

EXHIBIT 31.2

CERTIFICATION

I, Brian P. Monahan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bruker Corporation;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2010	By:	/s/ BRIAN P. MONAHAN
			Brian P. Monahan Chief Financial Officer (Principal Financial Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bruker Corporation (the “Company”) on Form 10-Q for the three months ended June 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Frank H. Laukien, as President, Chief Executive Officer and Chairman of the Board of Directors of the Company, and Brian P. Monahan, as Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2010	By:	/s/ FRANK H. LAUKIEN, PH.D.
		Frank H. Laukien, Ph.D. President, Chief Executive Officer and Chairman (Principal Executive Officer)

Date: August 9, 2010	By:	/s/ BRIAN P. MONAHAN
		Brian P. Monahan Chief Financial Officer (Principal Financial Officer)